[{"text": "Cole Pinnow Bought 2,085% More Shares In Cogent Biosciences editorial-team@simplywallst.com (Simply Wall St) Fri, Jan 17, 2025, 1:35 PM 3 min read In This Article: COGT -3.44% Potential Cogent Biosciences, Inc. ( NASDAQ:COGT ) shareholders may wish to note that insider Cole Pinnow recently bought US$332k worth of stock, paying US$7.60 for each share. That certainly has us anticipating the best, especially since they thusly increased their own holding by 2,085%, potentially signalling some real optimism. See our latest analysis for Cogent Biosciences The Last 12 Months Of Insider Transactions At Cogent Biosciences Notably, that recent purchase by Cole Pinnow is the biggest insider purchase of Cogent Biosciences shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$8.13. That means they have been optimistic about the company in the past, though they may have changed their mind. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Cogent Biosciences insider decided to buy shares at close to current prices. The only individual insider to buy over the last year was Cole Pinnow. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction! NasdaqGS:COGT Insider Trading Volume January 17th 2025 There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Does Cogent Biosciences Boast High Insider Ownership? I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. From what we can see in our data, insiders own only about US$16k worth of Cogent Biosciences shares. We might be missing something but that seems like very low insider ownership. What Might The Insider Transactions At Cogent Biosciences Tell Us? It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Cogent Biosciences stock. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For example, Cogent Biosciences has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about. Story Continues Of course Cogent Biosciences may not be the best stock to buy . So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2025-01-17T10:35:12+00:00", "sentiment": {"score": 0.03697779029607773, "confidence": 0.06518949568271637, "probabilities": {"positive": 0.06518949568271637, "negative": 0.02821170538663864, "neutral": 0.9065988063812256}}, "embedding": [-0.07334938645362854, -0.18465711176395416, 0.03158502280712128, -0.0204329751431942, 0.028044510632753372, -0.044599033892154694, 0.11738353967666626, 0.0880880206823349, 0.02561102993786335, 0.136690154671669, -0.008283231407403946, 0.03040059097111225, -0.08014403283596039, -0.03263190761208534, -0.1850356161594391, -0.046111807227134705, -0.026834188029170036, -0.13506193459033966, -0.1666724979877472, 0.061457134783267975, -0.3137108087539673, -0.12423600256443024, 0.0016491422429680824, 0.08534511923789978, 0.08753161132335663, 0.004133553244173527, -0.013657497242093086, -0.11147686839103699, -0.07297883927822113, -0.09008002281188965, -0.032433994114398956, 0.012213649228215218, 0.171441912651062, 0.04655051231384277, -0.04232535883784294, -0.039717718958854675, 0.022939439862966537, -0.09949873387813568, 0.19003194570541382, -0.00018971692770719528, 0.08206792175769806, 0.05327685922384262, -0.0546824149787426, 0.05261601135134697, -0.1645241379737854, -0.07657851278781891, 0.007428495213389397, -0.07751673460006714, 0.05924586206674576, -0.03849329799413681, -0.08495677262544632, -0.10346908867359161, 0.0821247398853302, -0.09789861738681793, 0.044051870703697205, 0.1374877691268921, -0.0689651295542717, -0.18848872184753418, 0.11357623338699341, -0.04465090110898018, 0.2140514850616455, -0.0752401053905487, 0.07552263885736465, 0.008590316399931908, 0.2607908248901367, -0.07733656466007233, 0.12408947944641113, 0.039188217371702194, 0.0942455306649208, -0.12096567451953888, 0.2463349550962448, -0.014406933449208736, -0.02628861926496029, -0.0071364473551511765, -0.08915513753890991, 0.137905091047287, 0.056005049496889114, -0.019347649067640305, 0.038028210401535034, -0.11281585693359375, -0.05493394285440445, 0.143524169921875, -0.07702058553695679, -0.10165441036224365, -0.10745500773191452, -0.006315441336482763, -0.0010798186995089054, 0.0958358645439148, 0.0178933534771204, 0.04409567266702652, 0.019945895299315453, -0.07434698939323425, -0.008874155580997467, -0.03605036437511444, -0.08642664551734924, 0.12920886278152466, -0.11915859580039978, 0.17003236711025238, -0.10727821290493011, -0.059282273054122925, 0.09464766085147858, 0.23347175121307373, -0.04037148505449295, 0.0142239760607481, 0.007185264490544796, -0.128917396068573, 0.06497450172901154, -0.04670054838061333, 0.04138295352458954, 0.11554251611232758, -0.21056842803955078, 0.03899167478084564, -0.20155972242355347, -0.04424348473548889, 0.02119978331029415, 0.20995815098285675, 0.04403300583362579, -0.006308992858976126, 0.15307435393333435, -0.02875964529812336, 0.17048731446266174, 0.10893051326274872, -0.09606006741523743, -0.0832766592502594, -0.006612688302993774, 0.06675850600004196, -0.10657520592212677, 1.1701752388848167e-32, 0.11072322726249695, 0.09886730462312698, -0.09573455154895782, 0.00791451521217823, -0.05595569312572479, 0.01821207068860531, -0.01678728125989437, -0.11142541468143463, -0.06001138687133789, 0.03427448868751526, -0.1200796589255333, 0.1607378125190735, -0.009060367941856384, -0.05516871437430382, -0.21796348690986633, -0.02376614511013031, -0.09698356688022614, 0.016931792721152306, -0.08307254314422607, 0.026527173817157745, 0.04464513808488846, 0.2392989695072174, -0.13022229075431824, 0.04901809245347977, -0.029538126662373543, -0.19748443365097046, -0.08731196820735931, -0.0022977348417043686, 0.06328148394823074, 0.06214585527777672, -0.05072881653904915, 0.07125820219516754, 0.0687698945403099, 0.06393983215093613, 0.017593052238225937, 0.01322137750685215, -0.13996128737926483, -0.15589222311973572, 0.12446227669715881, 0.037887685000896454, 0.08956466615200043, 0.032916098833084106, -0.0772821307182312, -0.12166491150856018, -0.05185166373848915, 0.008633019402623177, -0.14020892977714539, 0.07983368635177612, 0.06587877124547958, 0.00805569626390934, -0.03798440098762512, 0.06458274275064468, 0.0013810358941555023, -0.07555903494358063, -0.01703701913356781, 0.04346124082803726, -0.0007119700312614441, -0.1312864124774933, 0.11665351688861847, 0.09301955252885818, -0.04095296189188957, 0.14449815452098846, 0.02221515402197838, 0.13983070850372314, -0.19527706503868103, 0.12204517424106598, -0.03589876741170883, 0.13747578859329224, -0.04304521530866623, 0.21451571583747864, -0.1327020674943924, -0.03194940462708473, 0.004410065710544586, -0.036702774465084076, 0.01667334884405136, -0.0416238009929657, 0.11732122302055359, 0.022595789283514023, -0.003385785035789013, 0.07282611727714539, 0.059425026178359985, -0.011166132055222988, 0.11307977139949799, 0.07631638646125793, -0.04647449404001236, 0.10459381341934204, -0.020544808357954025, 0.033070482313632965, -0.04384647309780121, 0.0074864039197564125, 0.04094488546252251, -0.0036078430712223053, 0.058593813329935074, 0.04006832838058472, -0.1719529628753662, -1.2812155209361608e-32, -0.08547887206077576, -0.043589841574430466, -0.12307164818048477, -0.23516151309013367, -0.11722184717655182, 0.039880238473415375, 0.0724010020494461, -0.007687684148550034, -0.14356951415538788, -0.08462868630886078, 0.014009779319167137, 0.06934856623411179, -0.014055116102099419, 0.031032584607601166, -0.10416001826524734, 0.09315825253725052, 0.10437852144241333, -0.015599066391587257, 0.07731606066226959, -0.13936734199523926, -0.08987750113010406, 0.16241782903671265, -0.15255455672740936, 0.18463921546936035, 0.04016313701868057, 0.12420031428337097, 0.012905934825539589, 0.12659761309623718, -0.03698191046714783, -0.0599467009305954, -0.03194013983011246, -0.06569765508174896, -0.11682013422250748, 0.043924711644649506, -0.034289468079805374, -0.025612730532884598, -0.011839195154607296, -0.15337815880775452, 0.019997630268335342, -0.06487619131803513, 0.005455806851387024, 0.06016572564840317, 0.07569941133260727, -0.10253578424453735, 0.08811753243207932, -0.002759060822427273, 0.03876896947622299, -0.2051902711391449, 0.05180765688419342, 0.24220997095108032, 0.024396441876888275, 0.039945267140865326, 0.07879146933555603, 0.15214772522449493, -0.1149405986070633, 0.030726846307516098, 0.04816871136426926, 0.1446819007396698, 0.131250262260437, -0.05288226157426834, 0.03296869620680809, 0.24155761301517487, -0.05428800731897354, 0.0616740919649601, -0.057559046894311905, 0.004384415224194527, -0.0055348314344882965, -0.11053769290447235, -0.1609000265598297, -0.10550083220005035, -0.011249946430325508, -0.17968134582042694, 0.018180271610617638, -0.25153231620788574, 0.01364085078239441, 0.3528168499469757, -0.14039938151836395, -0.19475728273391724, -0.09688655287027359, -0.01327461376786232, -0.02188187651336193, -0.021288787946105003, 0.20783965289592743, 0.1406419426202774, -0.0007556877098977566, 0.06769127398729324, -0.10537392646074295, 0.06274813413619995, -0.02029777504503727, -0.00013686588499695063, -0.16805852949619293, -0.30260711908340454, -0.12931056320667267, -0.15335163474082947, 0.07528017461299896, -1.0005416584135673e-07, 0.06394357979297638, 0.045641474425792694, 0.012542502023279667, 0.006081453524529934, 0.21543371677398682, 0.0340040884912014, -0.03536945581436157, 0.005680216941982508, -0.010689491406083107, 0.24418938159942627, 0.09838850796222687, -0.04119621962308884, -0.18543587625026703, -0.0004186793230473995, -0.08069275319576263, 0.037309542298316956, -0.12671132385730743, -0.0607343390583992, -0.06249357759952545, -0.08203911781311035, -0.0689273253083229, 0.13579875230789185, 0.09439801424741745, 0.08645536005496979, -0.1342906951904297, 0.14167137444019318, -0.0494445264339447, 0.19425445795059204, 0.03252659738063812, 0.032903578132390976, 0.0451703816652298, -0.026610804721713066, 0.12265315651893616, 0.012913737446069717, 0.07794263958930969, 0.06620275229215622, 0.0725863128900528, 0.07737249881029129, -0.13718906044960022, 0.22604039311408997, -0.06633730232715607, -0.13364288210868835, -0.06363043934106827, 0.014386257156729698, 0.029245246201753616, -0.0851922333240509, -0.20057043433189392, -0.004427917301654816, 0.097636878490448, -0.08090388774871826, 0.20976820588111877, -0.1029740571975708, 0.009906668215990067, 0.2290237545967102, 0.025840314105153084, -0.03584938496351242, -0.14732623100280762, 0.06331230700016022, -0.2202145755290985, -0.0246006827801466, 0.03479259833693504, -0.21428252756595612, 0.027218345552682877, 0.13881626725196838], "changes": {"1wk": 10.709846064133709}}, {"text": "This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year editorial-team@simplywallst.com (Simply Wall St) Fri, Jan 17, 2025, 1:40 PM 3 min read In This Article: COGT -3.44% Looking at Cogent Biosciences, Inc.'s ( NASDAQ:COGT ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing. See our latest analysis for Cogent Biosciences The Last 12 Months Of Insider Transactions At Cogent Biosciences Notably, that recent purchase by Cole Pinnow is the biggest insider purchase of Cogent Biosciences shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$8.13. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Cogent Biosciences share holders is that an insider was buying at near the current price. The only individual insider to buy over the last year was Cole Pinnow. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! NasdaqGS:COGT Insider Trading Volume January 17th 2025 There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Does Cogent Biosciences Boast High Insider Ownership? Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Our information indicates that Cogent Biosciences insiders own about US$16k worth of shares. We might be missing something but that seems like very low insider ownership. So What Do The Cogent Biosciences Insider Transactions Indicate? It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Cogent Biosciences insiders are expecting a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 3 warning signs for Cogent Biosciences you should be aware of, and 1 of these doesn't sit too well with us. Story Continues If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2025-01-17T10:40:01+00:00", "sentiment": {"score": 0.0061204694211483, "confidence": 0.04072476550936699, "probabilities": {"positive": 0.04072476550936699, "negative": 0.03460429608821869, "neutral": 0.924670934677124}}, "embedding": [-0.08708646893501282, -0.1385372281074524, 0.07258391380310059, -0.0385572724044323, 0.06312669813632965, -0.008872972801327705, 0.06925056129693985, 0.08745807409286499, 0.05783417075872421, 0.16461776196956635, 0.011117924004793167, 0.03703366219997406, -0.06826138496398926, 0.0025933790020644665, -0.14858683943748474, -0.061784785240888596, -0.02917112410068512, -0.06618093699216843, -0.19527801871299744, 0.04382432997226715, -0.22982701659202576, -0.15434706211090088, 0.004946650005877018, 0.06124451383948326, 0.04660075902938843, 0.0002170167863368988, -0.017779788002371788, -0.09040796756744385, -0.08881156146526337, -0.0546310730278492, -0.036078523844480515, 0.06033644825220108, 0.10689252614974976, 0.018989652395248413, -0.06242549791932106, -0.027788950130343437, -0.01912965625524521, -0.06789953261613846, 0.1887597143650055, 0.0022578276693820953, 0.0330410860478878, 0.050281643867492676, -0.048440247774124146, 0.027824433520436287, -0.1691197156906128, -0.08770295977592468, -0.003167477436363697, -0.08089179545640945, 0.008420012891292572, 0.005363015457987785, -0.14169301092624664, -0.10342991352081299, 0.0615195631980896, -0.1404140591621399, 0.055323973298072815, 0.1431276798248291, -0.05870705097913742, -0.18962696194648743, 0.06993313878774643, -0.0693863108754158, 0.2082374393939972, -0.0718601644039154, 0.04240787401795387, -0.02410786971449852, 0.21786415576934814, -0.043757323175668716, 0.11428727209568024, 0.016550634056329727, 0.08340245485305786, -0.08003883808851242, 0.24584056437015533, -0.012097823433578014, -0.035790517926216125, -0.045359283685684204, -0.07699736952781677, 0.158823162317276, 0.05094730108976364, 0.01388573832809925, 0.056784022599458694, -0.1331298053264618, -0.0014234064146876335, 0.15357810258865356, -0.06187998503446579, -0.07617063820362091, -0.046072471886873245, -0.0021432838402688503, 0.026232300326228142, 0.061065491288900375, -0.026206009089946747, 0.054007638245821, 0.05225133150815964, -0.08435516059398651, -0.053497038781642914, -0.01840355060994625, -0.051097363233566284, 0.06864107400178909, -0.1373412311077118, 0.16418716311454773, -0.024028286337852478, -0.05330175906419754, 0.07883672416210175, 0.17933562397956848, -0.05853291600942612, -0.006213177926838398, -0.027123916894197464, -0.15011999011039734, 0.04986140504479408, -0.08882017433643341, 0.06727814674377441, 0.12090526521205902, -0.2258589118719101, 0.058256976306438446, -0.13471874594688416, -0.00545912329107523, 0.02098992094397545, 0.17740017175674438, 0.00010647997260093689, 0.043501511216163635, 0.14166373014450073, -0.05973450094461441, 0.168186217546463, 0.10477545112371445, -0.039925988763570786, -0.0492243617773056, 0.00418505584821105, 0.05022379383444786, -0.07613949477672577, 1.2484358324059244e-32, 0.07689788937568665, 0.09181781113147736, -0.042929403483867645, 0.03414371237158775, -0.0687846690416336, 0.03355918824672699, -0.02623583748936653, -0.08318524807691574, -0.027442965656518936, 0.00699989078566432, -0.1141560971736908, 0.15593165159225464, -0.009289508685469627, -0.0760183036327362, -0.18089228868484497, -0.04412875697016716, -0.07641785591840744, -0.0018448582850396633, -0.06948137283325195, -0.006276322994381189, 0.05391273275017738, 0.17902609705924988, -0.12164875864982605, 0.025833331048488617, -0.01839921623468399, -0.21775811910629272, -0.09043212234973907, 0.04200492799282074, -0.02505902573466301, 0.05270738899707794, -0.011849750764667988, 0.004055999219417572, -0.009623152203857899, 0.033149994909763336, 0.018844716250896454, 0.02530919760465622, -0.1443798989057541, -0.13797512650489807, 0.12822076678276062, -0.010612037032842636, 0.05550142377614975, 0.03750001639127731, -0.07262696325778961, -0.09731479734182358, -0.029325567185878754, 0.0031075654551386833, -0.15346968173980713, 0.037264976650476456, 0.08082171529531479, 0.008094806224107742, -0.029859449714422226, 0.043132200837135315, 0.03186310455203056, -0.08355845510959625, -0.013915221206843853, 0.07909948378801346, 0.03358812630176544, -0.09415331482887268, 0.09168919175863266, 0.10607604682445526, -0.03456556797027588, 0.15157531201839447, 0.03140636906027794, 0.10342629253864288, -0.16481974720954895, 0.12094999104738235, -0.04120836406946182, 0.10363634675741196, -0.008312750607728958, 0.15166804194450378, -0.10568377375602722, 0.005201986525207758, 0.0034698210656642914, -0.011646461673080921, -0.027149830013513565, -0.03453613817691803, 0.06714807450771332, 0.047505635768175125, -0.024700865149497986, 0.052412986755371094, 0.061686839908361435, 0.010600300505757332, 0.07920987904071808, 0.05065447464585304, -0.04095058888196945, 0.029235154390335083, -0.002760607749223709, 0.027859285473823547, -0.020323820412158966, 0.06729324907064438, 0.04256793111562729, -0.00714501179754734, 0.05722595378756523, 0.09822101891040802, -0.14412352442741394, -1.3913171707483734e-32, -0.10682977735996246, -0.04798632860183716, -0.050159454345703125, -0.23315289616584778, -0.11935554444789886, 0.03079899586737156, 0.03889882564544678, -0.07828627526760101, -0.10561785101890564, -0.12678977847099304, 0.022123726084828377, 0.051866739988327026, -0.02443614974617958, 0.013274243101477623, -0.11212160438299179, 0.08717559278011322, 0.07101377844810486, -0.06021139770746231, 0.09163281321525574, -0.09699774533510208, -0.05432944744825363, 0.1642860621213913, -0.138639897108078, 0.12327466905117035, 0.05147085338830948, 0.09242859482765198, 0.05973588675260544, 0.14217053353786469, -0.02959652990102768, -0.11126530915498734, -0.03343094512820244, -0.08934410661458969, -0.12333191931247711, 0.036534421145915985, -0.0032322239130735397, -0.06384695321321487, 0.00636973325163126, -0.16541628539562225, 0.006538604386150837, 0.009945718571543694, 0.014047645032405853, 0.07124142348766327, 0.06540868431329727, -0.07757383584976196, 0.08328692615032196, -0.01046551950275898, 0.021125447005033493, -0.19211888313293457, 0.05437649041414261, 0.20331569015979767, 0.034483008086681366, 0.057969942688941956, 0.03820958733558655, 0.13133999705314636, -0.09054751694202423, 0.06830514222383499, 0.04406782239675522, 0.12114399671554565, 0.10411451756954193, -0.043120019137859344, 0.029803279787302017, 0.22615854442119598, -0.056278057396411896, 0.009865018539130688, -0.049616217613220215, 0.029150500893592834, 0.005987448617815971, -0.13998368382453918, -0.10484197735786438, -0.06423377245664597, -0.01841321773827076, -0.1722283959388733, -0.03396478667855263, -0.1969992220401764, 0.016396086663007736, 0.24415703117847443, -0.15303462743759155, -0.20029157400131226, -0.07893860340118408, -0.033737488090991974, -0.02815985679626465, -0.025924423709511757, 0.17224758863449097, 0.11530406773090363, -0.00492225494235754, 0.06928987801074982, -0.060644350945949554, 0.029926598072052002, -0.02090061642229557, -0.02841229923069477, -0.11646769940853119, -0.28490060567855835, -0.08599447458982468, -0.18012003600597382, 0.046374496072530746, -1.0048993459577105e-07, 0.05506481975317001, 0.029455550014972687, 0.0346280038356781, 0.019544806331396103, 0.20867973566055298, -0.03219040483236313, 0.006800282746553421, -0.012093453668057919, -0.00849686935544014, 0.2078651636838913, 0.08019129186868668, -0.011731293052434921, -0.200898677110672, -0.0002808431163430214, -0.04407470300793648, -0.008625078946352005, -0.11258327960968018, -0.056418899446725845, -0.05879237502813339, -0.07055339962244034, -0.07232876121997833, 0.13730497658252716, 0.06962823867797852, 0.1239999532699585, -0.11146996915340424, 0.1205877959728241, -0.0262458473443985, 0.12824377417564392, 0.00848071463406086, 0.06669123470783234, 0.04552070423960686, -0.005464877933263779, 0.12754040956497192, -0.001034630462527275, 0.0745667964220047, 0.06805753707885742, 0.04162873327732086, 0.07999004423618317, -0.10094141960144043, 0.21756356954574585, -0.023339278995990753, -0.0703917145729065, -0.07221636176109314, 0.07509294152259827, 0.03993994742631912, -0.07453376799821854, -0.14810268580913544, -0.01755470409989357, 0.05044287443161011, -0.09377209097146988, 0.20059549808502197, -0.09354817867279053, 0.014654704369604588, 0.19037018716335297, -0.0228472538292408, 0.016232753172516823, -0.1378050595521927, 0.06229599565267563, -0.19184795022010803, 0.01586310751736164, 0.04654094949364662, -0.1315212845802307, 0.029176604002714157, 0.12248808145523071], "changes": {"1wk": 10.709846064133709}}, {"text": "PREMIUM Cogent Biosciences Insider Bought Shares Worth $332,413, According to a Recent SEC Filing MT Newswires Wed, Jan 15, 2025, 3:06 PM Cole Pinnow, Chief Commercial Officer, on January 14, 2025, executed a purchase for 43,750 shares in PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2025-01-15T12:06:40+00:00", "sentiment": {"score": 0.034586756490170956, "confidence": 0.04905450716614723, "probabilities": {"positive": 0.04905450716614723, "negative": 0.014467750675976276, "neutral": 0.9364777207374573}}, "embedding": [-0.0727493092417717, -0.07974474877119064, 0.018748100847005844, 0.0007299539283849299, -0.00953137967735529, -0.012766591273248196, 0.06258506327867508, 0.09457207471132278, -0.013433043844997883, 0.09857313334941864, 0.08478640019893646, 0.026868123561143875, -0.026129936799407005, -0.07602555304765701, -0.11195139586925507, -0.0305832177400589, 0.03156726062297821, -0.19277358055114746, -0.021695151925086975, -0.0732802152633667, -0.1843818575143814, -0.10578324645757675, -0.07509034126996994, 0.05879891291260719, 0.12624847888946533, -0.016043497249484062, -0.04368487000465393, -0.10993039608001709, 0.08446801453828812, -0.04616566747426987, -0.006432027090340853, -0.07517500221729279, 0.16523197293281555, 0.0031756479293107986, -0.0037703020498156548, -0.05798855051398277, 0.07408589124679565, -0.07149025052785873, 0.1374375820159912, 0.048883046954870224, 0.054516345262527466, 0.007256651762872934, -0.16164158284664154, 0.051933225244283676, -0.08025418221950531, -0.03432343900203705, 0.0032070381566882133, -0.007981172762811184, 0.1679607629776001, 0.09621195495128632, -0.09337244182825089, -0.09904655814170837, 0.03424534201622009, -0.1271858662366867, 0.0007378279115073383, 0.052348919212818146, -0.11431922763586044, -0.014465835876762867, 0.023087328299880028, -0.12100442498922348, 0.16635607182979584, -0.1811644434928894, 0.08329847455024719, 0.025138776749372482, 0.0638369619846344, -0.031455982476472855, 0.06840366125106812, 0.07895815372467041, 0.06515524536371231, -0.10771897435188293, 0.1961495727300644, 0.0772993341088295, 0.06178298592567444, -0.06265053153038025, -0.037450093775987625, 0.16403913497924805, 0.03263217583298683, -0.13143062591552734, 0.004653214942663908, -0.09325998276472092, -0.06496555358171463, -0.054291706532239914, -0.04622345045208931, -0.03912622854113579, -0.005183503497391939, 0.006801709998399019, 0.023158516734838486, 0.07106249779462814, 0.07470604032278061, -0.05718625709414482, 0.03860560432076454, -0.139068141579628, -0.011817432940006256, -0.10826583206653595, -0.17150284349918365, 0.18299216032028198, -0.24547052383422852, 0.04600384086370468, -0.12273642420768738, -0.04296069219708443, 0.005698870867490768, 0.1486665904521942, 0.03718084469437599, -0.017506662756204605, 0.07399395853281021, -0.07498730719089508, 0.13238726556301117, 0.11272462457418442, 0.11738599091768265, 0.12736395001411438, -0.100080206990242, 0.02364472858607769, -0.08712147921323776, -0.018229233101010323, 0.09712773561477661, 0.1679178923368454, 0.03224184364080429, 0.027119336649775505, 0.15922515094280243, -0.08255153149366379, 0.21219892799854279, -0.011700133793056011, -0.08424414694309235, -0.07828231155872345, -0.12555821239948273, -0.03633718565106392, -0.012521252036094666, 9.592975767558462e-33, 0.023310208693146706, 0.19336143136024475, -0.018268674612045288, -0.011487633921205997, -0.03426971286535263, 0.0436667762696743, 0.11042097955942154, -0.14172443747520447, -0.10569952428340912, 0.011562651954591274, -0.13067756593227386, 0.175277978181839, 0.0031890252139419317, 0.038480546325445175, -0.21313342452049255, -0.07298922538757324, -0.016448739916086197, 0.03589154779911041, 0.045723807066679, -0.0036491123028099537, 0.0074332295916974545, 0.10300978273153305, -0.12164155393838882, 0.02492647059261799, -0.06855979561805725, -0.09031033515930176, 0.0033880111295729876, 0.006144235841929913, 0.15378175675868988, 0.07524502277374268, -0.0633377879858017, 0.07947030663490295, 0.09754955768585205, 0.09894714504480362, -0.01595417410135269, 0.08233574032783508, -0.1341117024421692, -0.10205555707216263, 0.13492059707641602, -0.018223978579044342, 0.08540217578411102, 0.036298610270023346, -0.006284892093390226, -0.14441603422164917, -0.17968931794166565, 0.005247730761766434, -0.1391879916191101, -0.0176013745367527, 0.1386156976222992, -0.08093912154436111, -0.08718053251504898, 0.09038908779621124, -0.1116228699684143, 0.05650320276618004, -0.06272833049297333, -0.022120388224720955, -0.0634404867887497, -0.04512779042124748, 0.12753897905349731, 0.06292004138231277, 0.022995004430413246, 0.10397852957248688, 0.09076333791017532, 0.13990025222301483, -0.10307657718658447, 0.14635184407234192, -0.1027253195643425, 0.0008229022496379912, -0.05559958145022392, 0.18956971168518066, -0.024186203256249428, -0.1459418386220932, -0.06908927857875824, -0.09299895912408829, -0.05690377950668335, -0.06728474050760269, 0.06123672425746918, -0.09644737094640732, 0.10827876627445221, 0.13863828778266907, 0.04085322096943855, -0.11713089793920517, 0.016448013484477997, 0.09536735713481903, -0.029067708179354668, 0.21671517193317413, -0.11284943670034409, 0.12543390691280365, 0.09485069662332535, -0.01994291879236698, 0.14248374104499817, 0.045914601534605026, -0.04704669117927551, -0.01156412623822689, -0.19773094356060028, -1.1050363949283504e-32, -0.08931301534175873, 0.025951698422431946, -0.027576206251978874, -0.1151844933629036, -0.22059398889541626, 0.08253026753664017, -0.009273961186408997, 0.07137642800807953, -0.11219629645347595, 0.0634230300784111, 0.08622080832719803, 0.14640282094478607, -0.1471375972032547, 0.019287237897515297, -0.013350220397114754, 0.13474825024604797, 0.0024896999821066856, -0.0517801009118557, 0.1462782621383667, -0.029566030949354172, -0.03151961788535118, 0.08689160645008087, -0.029122214764356613, 0.24892668426036835, 0.04358861222863197, 0.10938949137926102, 0.04383159056305885, 0.08994191884994507, 0.08200880140066147, 0.003339241724461317, -0.009827653877437115, -0.09032732248306274, -0.10783352702856064, 0.027575552463531494, -0.03221190348267555, -0.07084766030311584, 0.07833123952150345, 0.028504453599452972, 0.1227681115269661, -0.03557746857404709, 0.026778405532240868, -0.10995863378047943, 0.1170157715678215, 0.04046837240457535, 0.19435839354991913, -0.08392972499132156, 0.013488327153027058, -0.17212265729904175, 0.06784499436616898, 0.14546005427837372, -0.016534609720110893, -0.011936168186366558, 0.05469983071088791, 0.08690417557954788, -0.19389112293720245, 0.04621729254722595, -0.008646924048662186, 0.14471371471881866, 0.0817144513130188, -0.09348586946725845, -0.0368991456925869, 0.21712642908096313, -0.14925533533096313, 0.032578494399785995, -0.1419278383255005, 0.037021055817604065, 0.014206049032509327, -0.07013414800167084, -0.18572084605693817, -0.08889267593622208, -0.08427771925926208, -0.07394291460514069, 0.03378840163350105, -0.3008270263671875, -0.03667730093002319, 0.2298307716846466, -0.12818750739097595, -0.1026001125574112, -0.05049992352724075, 0.12484584003686905, -0.040025945752859116, -0.021685512736439705, 0.1968197524547577, -0.003314655041322112, -0.04267293959856033, -0.05749611556529999, -0.035634417086839676, 0.05424712598323822, -0.06255381554365158, 0.058352015912532806, -0.2207704782485962, -0.1320275217294693, -0.07228260487318039, -0.10604605078697205, 0.09327243268489838, -9.985306803628191e-08, 0.06815412640571594, 0.03845326974987984, 0.15841799974441528, 0.02756796032190323, 0.13846614956855774, 0.0591144785284996, -0.15367144346237183, 0.032032933086156845, 0.0021368847228586674, 0.21119658648967743, -0.09967024624347687, -0.08670243620872498, -0.1309804916381836, 0.06795107573270798, -0.19958779215812683, -0.03089255653321743, -0.06772776693105698, 0.0629182755947113, 0.04425765201449394, -0.05772147327661514, -0.016987241804599762, 0.1026701033115387, 0.16162480413913727, -0.021341878920793533, -0.12374267727136612, 0.13981761038303375, 0.010037075728178024, 0.023937057703733444, -0.01932123303413391, 0.005161329638212919, -0.012354728765785694, 0.06398452073335648, 0.08195646852254868, 0.1209261491894722, 0.048261500895023346, -0.04956838861107826, 0.030893145129084587, 0.0730704665184021, -0.2299286127090454, 0.13714279234409332, -0.07187708467245102, -0.05176885798573494, -0.002189110964536667, -0.001083819312043488, 0.0647931769490242, 0.010803202167153358, -0.18784146010875702, -0.0988800972700119, 0.09277226030826569, -0.0004936276818625629, 0.22832347452640533, -0.010580259375274181, -0.04830518364906311, 0.16200828552246094, -0.047562457621097565, -0.0919603481888771, -0.1438923329114914, -0.036591384559869766, -0.18008558452129364, 0.03959640860557556, -0.014809546060860157, -0.31678324937820435, -0.04312451183795929, -0.04011629894375801], "changes": {"1wk": 0.9852207491816546}}, {"text": "Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics Cogent Biosciences, Inc. Mon, Jan 13, 2025, 4:00 PM 7 min read In This Article: COGT -3.44% Cogent Biosciences, Inc. \u2022 Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025 \u2022 Plan to report top-line results from pivotal PEAK Phase 3 trial in 2 nd -line GIST patients by end of 2025 \u2022 Plan to report top-line results from registration-directed APEX trial in AdvSM patients in 2H 2025 \u2022 Company to present at\u00a0J.P. Morgan\u00a043 rd annual healthcare conference tomorrow, Tuesday, January 14 at\u00a07:30 a.m. PT\u00a0/10:30 a.m. ET WALTHAM, Mass. and BOULDER, Colo., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company\u2019s key 2025 milestones ahead of its presentation at J.P. Morgan\u2019s 43rd annual healthcare conference. \u201c2025 will be a transformational year at Cogent Biosciences,\u201d said Andrew Robbins, President and Chief Executive Officer. \u201cDuring the year, we plan to report top-line results from all three registration-directed bezuclastinib studies, and if successful, move forward with our first New Drug Application (NDA) submission by the end of 2025. With both SUMMIT and PEAK enrollment finishing several months ahead of schedule, we are confident that physicians and patients are highly aware of bezuclastinib\u2019s potential and are also eagerly awaiting these clinical trial results. We believe bezuclastinib could change the lives of thousands of patients fighting SM and GIST and has the potential to be the first potent, CNS-sparing, selective KIT mutant inhibitor. In addition, we continue to advance our pipeline of novel small molecule programs, including an ongoing Phase 1 study of our novel FGFR2 inhibitor, CGT4859, and plan to file INDs for both our ErbB2 and PI3K\u03b1 programs during the year. With a strong balance sheet, we are well positioned to prepare Cogent for our evolution into a commercial-stage company.\u201d In 2025, the Company plans to achieve the following milestones : Bezuclastinib \u2013 Systemic Mastocytosis (SM) Report top-line results in July 2025 from the SUMMIT trial. SUMMIT is a registration-directed, global, randomized, placebo-controlled trial of bezuclastinib in patients with Non-Advanced Systemic Mastocytosis (NonAdvSM). Report top-line results during the second half of 2025 from the APEX trial. APEX is a registration-directed, global, open-label trial of bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM). Submit the first bezuclastinib New Drug Application (NDA) by the end of 2025. Story Continues Bezuclastinib \u2013 Gastrointestinal Stromal Tumors (GIST) Report top-line results by the end of 2025 from the pivotal Phase 3 PEAK trial. PEAK is a global, blinded, randomized clinical trial studying the combination of bezuclastinib and sunitinib versus sunitinib alone in patients with imatinib-resistant gastrointestinal stromal tumors (GIST). Bezuclastinib - Expanded Access Program During Q1 2025, initiate Expanded Access Programs (EAP) in the U.S. for SM and GIST patients to receive investigational bezuclastinib after meeting certain eligibility criteria. CGT4859 (FGFR2 inhibitor) Enroll patients in the ongoing Phase 1 trial with CGT4859, a reversible, selective FGFR2 inhibitor in patients with documented FGFR mutations, including advanced cholangiocarcinoma. The trial is designed to explore the safety, tolerability and clinical activity of escalating doses of CGT4859 with a goal of selecting an active and well tolerated dose for further clinical investigation. Preclinical Pipeline Submit an IND application for CGT4255, a potent, selective ErbB2 inhibitor, highlighted by potential best-in-class brain-penetrant properties. Submit an IND application for CGT6737, a potent allosteric inhibitor of PI3K\u03b1, with 25-fold selectivity over PI3K\u03b1 WT. J.P. Morgan Presentation Details Cogent will participate in a presentation and Q&A session at the 43 rd Annual J.P. Morgan Healthcare Conference on\u00a0Tuesday, January 14, 2025, beginning at\u00a07:30 a.m. PT\u00a0(10:30 a.m. ET). A live webcast will be accessible in the \u201cInvestors & Media\u201d section of the company\u2019s website, www.cogentbio.com , and will be archived for 30 days following the event. Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cogent also announced today that, on January 7, 2025, the Compensation Committee of Cogent\u2019s Board of Directors, made up entirely of independent directors, approved the grant of \u201cinducement\u201d equity awards to nine new employees under the company\u2019s 2020 Inducement Plan with a grant date of January 13, 2025. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, nonqualified options to purchase 135,000 shares of Cogent common stock. Each option has a 10-year term, an exercise price equal to the closing price of Cogent\u2019s common stock on the grant date, and a 4-year vesting schedule with 25% vesting on the 1-year anniversary of the grant date and the remainder vesting in equal monthly installments over the subsequent 36 months, provided such employee remains employed through each such vesting date. About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3K\u03b1 and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter)\u00a0and LinkedIn . Information that may be important to investors will be routinely posted on our website and X . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: plans to report top-line results from SUMMIT in July 2025; plans to report top-line results from PEAK by the end of 2025; plans to report top-line results from APEX in the second half of 2025; plans to file the company\u2019s first NDA by the end of 2025; plans to file INDs for the company\u2019s ErbB2 and PI3K\u03b1 programs in 2025; plans to initiate EAPs in the United States for SM and GIST patients in the first quarter of 2025 and clinical development plans and timelines for the company\u2019s ongoing Phase 1 trial with CGT4859. The use of words such as, but not limited to, \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d or \u201cwould\u201d and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption \u201cRisk Factors\u201d in Cogent\u2019s most recent Quarterly Report on Form 10-Q filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Contact: Christi Waarich Senior Director, Investor Relations christi.waarich@cogentbio.com 617-830-1653 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2025-01-13T13:00:00+00:00", "sentiment": {"score": 0.7129076067358255, "confidence": 0.7240136861801147, "probabilities": {"positive": 0.7240136861801147, "negative": 0.011106079444289207, "neutral": 0.2648802399635315}}, "embedding": [-0.17405611276626587, -0.11149626970291138, 0.010339638218283653, -0.04562722146511078, 0.010463228449225426, -0.10232760012149811, -0.17361490428447723, 0.13352131843566895, 0.009306380525231361, 0.0668034702539444, -0.12749503552913666, 0.04606885090470314, -0.015537715516984463, 0.07020603120326996, -0.1203632801771164, 0.09282785654067993, -0.04275127127766609, 0.007676463574171066, -0.004163671284914017, -0.028172411024570465, 0.021343259140849113, 0.03680740296840668, 0.05888291448354721, 0.09431275725364685, -0.13321949541568756, -0.07889610528945923, -0.103616863489151, -0.08011217415332794, -0.20534679293632507, -0.014115284197032452, 0.04117283970117569, 0.11598443239927292, -0.003776084166020155, -0.04649621620774269, 0.0032025370746850967, 0.0033526262268424034, -0.06403867900371552, -0.0628548115491867, -0.013239828869700432, -0.11767448484897614, -0.027673106640577316, -0.05921673774719238, -0.08724093437194824, 0.11777377873659134, 0.12932395935058594, -0.1840561330318451, -0.10273458808660507, -0.039007898420095444, -0.057874999940395355, 0.14579927921295166, -0.15808090567588806, -0.1475645899772644, -0.07202904671430588, 0.03734803944826126, -0.06425394117832184, 0.03430209308862686, -0.08256282657384872, -0.08546217530965805, 0.0519358366727829, -0.02845427207648754, 0.0212683267891407, -0.08663420379161835, -0.055257704108953476, -0.0022851680405437946, 0.1593306064605713, 0.09980010986328125, 0.0502290315926075, 0.003598244860768318, -0.005564490333199501, 0.02415231429040432, 0.07241104543209076, -0.06493076682090759, 0.06172311305999756, 0.0986110121011734, 0.062360361218452454, 0.1215735524892807, 0.13025209307670593, 0.17741750180721283, 0.13932430744171143, -0.15052242577075958, -0.005964930169284344, 0.05539872497320175, 0.08612365275621414, -0.043818410485982895, -0.010555984452366829, 0.07793590426445007, -0.05797190964221954, 0.16358324885368347, 0.020241335034370422, 0.03382885083556175, 0.05300860106945038, -0.052684392780065536, 0.03238721564412117, 0.055351123213768005, -0.11063391715288162, 0.0030094152316451073, -0.07581047713756561, -0.01949525624513626, 0.07074137032032013, -0.052654534578323364, 0.019671397283673286, 0.0556640625, -0.04008927941322327, -0.05030472204089165, -0.011775979772210121, -0.050911352038383484, 0.16989272832870483, -0.024529755115509033, 0.07788365334272385, -0.003673960454761982, -0.05985589325428009, 0.0449354387819767, 0.08818319439888, -0.018319981172680855, -0.024550674483180046, 0.2664068341255188, 0.004863731563091278, 0.06141467019915581, 0.19570031762123108, 0.026141617447137833, 0.11746057868003845, 0.045406460762023926, -0.06854415684938431, -0.17129270732402802, 0.006530520506203175, 0.08148578554391861, -0.11216163635253906, 1.2259393684566813e-32, -0.03458268567919731, 0.07046077400445938, 0.12059159576892853, 0.15602245926856995, -0.03849952667951584, -0.05622507631778717, 0.08988617360591888, -0.09650910645723343, -0.18265263736248016, -0.07120206207036972, -0.16047681868076324, 0.014112871140241623, 0.03673529624938965, 0.10986004769802094, -0.12852612137794495, -0.18912267684936523, -0.013871049508452415, 0.09042905271053314, -0.055494923144578934, -0.027330607175827026, 0.04786442220211029, 0.06084837764501572, -0.06716786324977875, -0.0027584568597376347, 0.03492811694741249, 0.07071197032928467, -0.06549730151891708, 0.052267372608184814, 0.029988974332809448, 0.07260636240243912, -0.16675904393196106, 0.08106131851673126, 0.010695981793105602, -0.013863316737115383, -0.03745225816965103, -0.03744721785187721, -0.01719796471297741, -0.13695025444030762, 0.07616417109966278, 0.08794834464788437, 0.061349526047706604, 0.07570041716098785, -0.11567512899637222, -0.03458092361688614, 0.019253447651863098, -0.08031663298606873, -0.04485657811164856, 0.06025097519159317, 0.016922425478696823, -0.009966939687728882, -0.058111220598220825, 0.046716272830963135, -0.03783397376537323, -0.0041722641326487064, 0.0009367493912577629, 0.10780273377895355, -0.08880490064620972, -0.1032211184501648, 0.09528771042823792, 0.06163765490055084, 0.08563083410263062, 0.08107960969209671, -0.09540672600269318, 0.055715568363666534, -0.07785902917385101, 0.067344531416893, -0.014688795432448387, -0.02256416156888008, -0.05215827375650406, 0.1789284497499466, -0.06652255356311798, -0.047085441648960114, 0.1266353279352188, 0.06800244003534317, 0.18697543442249298, -0.0507587194442749, 0.18293654918670654, 0.044673800468444824, -0.025030100718140602, 0.0366036519408226, 0.05015094578266144, 0.05620196834206581, -0.22612708806991577, 0.10920585691928864, 0.02881254255771637, -0.08173473924398422, 0.13168394565582275, -0.026613149791955948, -0.1533806025981903, -0.01592288166284561, 0.19433008134365082, -0.08053417503833771, 0.03492416813969612, 0.13556738197803497, -0.09880262613296509, -1.114838254572682e-32, -0.022083420306444168, 0.0441579669713974, -0.020092003047466278, -0.07237549871206284, -0.03930864483118057, 0.06306561082601547, 0.12935981154441833, -0.1992044746875763, 0.06658947467803955, -0.11188910901546478, 0.08285320550203323, 0.052190303802490234, -0.008654589764773846, -0.05245084688067436, -0.1318645477294922, 0.07481096684932709, -0.02065243199467659, -0.12585942447185516, -0.09462142735719681, 0.045809220522642136, 0.09641421586275101, 0.1828513890504837, -0.17020100355148315, 0.01763000153005123, -0.0691036581993103, 0.09022324532270432, 0.14356109499931335, 0.09367620199918747, 0.10181170701980591, -0.11349176615476608, -0.131251722574234, -0.008784541860222816, -0.2544977366924286, -0.079743891954422, 0.006355486810207367, 0.010427003726363182, 0.08841104805469513, -0.19554443657398224, -0.04492012783885002, -0.14911726117134094, 0.019141938537359238, 0.027834907174110413, -0.17676807940006256, -0.009114755317568779, 0.08949998021125793, 0.06018446013331413, 0.06316865980625153, 0.04510655999183655, 0.081007219851017, 0.04711180552840233, -0.07311617583036423, 0.08231544494628906, -0.08769409358501434, 0.015246253460645676, -0.022670960053801537, -0.022159205749630928, 0.02043483406305313, -0.07636512815952301, -0.04982014745473862, 0.06442756205797195, -0.024581313133239746, 0.12663589417934418, 0.11185802519321442, -0.04830601438879967, 0.1578851342201233, 0.06495164334774017, 0.1362549215555191, 0.051569245755672455, 0.02788880281150341, -0.0015576104633510113, -0.14658352732658386, -0.010345208458602428, -0.022760525345802307, -0.13750341534614563, -0.008715101517736912, 0.04640769585967064, -0.055071569979190826, -0.16433149576187134, -0.18353185057640076, -0.0871095359325409, 0.008400863036513329, -0.0005511948838829994, 0.04067186266183853, 0.11665064096450806, 0.08364960551261902, 0.02583784982562065, 0.06155916675925255, 0.01870688796043396, 0.06629358977079391, 0.02006055973470211, -0.1182272881269455, -0.15248899161815643, -0.10319899022579193, 0.14874395728111267, 0.052833713591098785, -1.0023455843111151e-07, 0.08123709261417389, 0.060980424284935, 0.021365206688642502, -0.09887146949768066, 0.03782186284661293, 0.031755246222019196, -0.15557506680488586, 0.07914187759160995, 0.027543198317289352, 0.1677258014678955, 0.07899975776672363, 0.14098204672336578, -0.05267417058348656, 0.017158865928649902, -0.03821627050638199, 0.09788928180932999, -0.05534828081727028, 0.0038236016407608986, -0.05418332293629646, -0.1412321776151657, -0.1757906675338745, 0.07314892113208771, 0.026255935430526733, -0.08950207382440567, 0.0679229199886322, -0.15379194915294647, 0.005604670383036137, 0.18829447031021118, 0.01547862309962511, -0.1402127593755722, -0.09203094244003296, -0.05868466943502426, 0.03621767461299896, -0.015607153996825218, 0.0336882509291172, -0.13249728083610535, -0.018488937988877296, 0.1396152377128601, 0.10689599812030792, 0.12244337052106857, 0.03488647937774658, 0.11511731147766113, -0.043621405959129333, 0.12492954730987549, -0.041496362537145615, -0.17311933636665344, -0.08890963345766068, 0.007382296025753021, 0.05111968517303467, -0.12088488042354584, -0.08512932062149048, -0.02856479026377201, -0.06601567566394806, -0.042433902621269226, 0.02851705811917782, 0.2291821837425232, -0.07131082564592361, -0.04145936295390129, -0.019139640033245087, -0.03025205060839653, 0.08077073097229004, -0.16895776987075806, -0.001384800300002098, 0.006451956927776337], "changes": {"1wk": 6.076612296943436}}, {"text": "Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Cogent Biosciences, Inc. Wed, Jan 8, 2025, 4:00 PM 2 min read In This Article: COGT -3.44% Cogent Biosciences, Inc. WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 7:30 a.m. PT/10:30 a.m. ET. A live webcast will be available on the Investors & Media page of Cogent\u2019s website at investors.cogentbio.com . A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days. About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2, PI3K\u03b1 and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn . Information that may be important to investors will be routinely posted on our website and X . Contact: Christi Waarich Senior Director, Investor Relations christi.waarich@cogentbio.com 617-830-1653 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2025-01-08T13:00:00+00:00", "sentiment": {"score": 0.057915725745260715, "confidence": 0.07012248784303665, "probabilities": {"positive": 0.07012248784303665, "negative": 0.012206762097775936, "neutral": 0.917670726776123}}, "embedding": [-0.10706056654453278, -0.1043456494808197, -0.06803026795387268, -0.08827277272939682, 0.004483848810195923, -0.08355540782213211, -0.09669829159975052, 0.1329706460237503, -0.010831395164132118, 0.09480185061693192, -0.08466430008411407, 0.006091470830142498, -0.049570512026548386, 0.1308344006538391, -0.15193139016628265, 0.059131987392902374, -0.04429183900356293, 0.03622521460056305, -0.021168917417526245, -0.05725059285759926, 0.037556055933237076, 0.06929203867912292, 0.07817940413951874, 0.03607754781842232, -0.11927998811006546, -0.10139774531126022, -0.04017182067036629, -0.08286182582378387, -0.18662157654762268, 0.022596687078475952, -0.018300920724868774, 0.031051665544509888, 0.06251209229230881, -0.07663978636264801, -0.04608719423413277, 0.06323396414518356, 0.005522644147276878, -0.07139065861701965, 0.04165855422616005, -0.05064219981431961, -0.03527211770415306, 0.05201796442270279, -0.021150516346096992, 0.07579515874385834, 0.045344382524490356, -0.15552572906017303, -0.058469370007514954, -0.027814019471406937, 0.005813258700072765, 0.08384142071008682, -0.12281818687915802, -0.12539811432361603, -0.01308116503059864, 0.02028484083712101, 0.0329328253865242, -0.0009765550494194031, -0.13354550302028656, -0.020734334364533424, 0.03909814730286598, -0.05758531764149666, 0.10581067204475403, -0.07829733937978745, 0.03183474764227867, 0.05409068614244461, 0.1732248067855835, 0.10717716068029404, 0.0897161066532135, 0.0738859623670578, -0.003954421728849411, -0.05624109134078026, 0.12397129833698273, -0.04459965601563454, 0.044855084270238876, 0.15828867256641388, 0.03032114915549755, 0.13590751588344574, 0.11780031025409698, 0.11736243218183517, 0.1008858010172844, -0.06833714991807938, -0.06605115532875061, 0.047443121671676636, 0.16300642490386963, -0.033510513603687286, -0.02792166918516159, 0.033696286380290985, -0.05668746680021286, 0.15728391706943512, 0.08456116914749146, 0.04735393077135086, 0.058057788759469986, -0.055830202996730804, 0.03785645589232445, 0.046913109719753265, -0.0038800984621047974, -0.023772962391376495, 0.006243025418370962, 0.0017440058290958405, 0.0035684695467352867, -0.10553806275129318, -0.08826328068971634, 0.057284124195575714, -0.017369844019412994, 0.08215740323066711, 0.07587883621454239, -0.016661016270518303, 0.11139178276062012, 0.0738639160990715, 0.05865642800927162, 0.008310990408062935, -0.07580709457397461, 0.051805850118398666, 0.08015140146017075, -0.02478095330297947, -0.029274841770529747, 0.19350452721118927, 0.053282082080841064, 0.06316322088241577, 0.1406867504119873, 0.05351298302412033, 0.11540056765079498, -0.009535066783428192, -0.08600868284702301, -0.13007789850234985, 0.05033658817410469, 0.07099312543869019, -0.14977790415287018, 9.027980285307484e-33, 0.0009950613602995872, 0.11654680222272873, 0.14582836627960205, 0.07008399069309235, 0.052801620215177536, -0.06215726584196091, 0.023104291409254074, -0.1065472885966301, -0.15657056868076324, -0.07730470597743988, -0.09981978684663773, 0.05929826200008392, 0.06255200505256653, 0.03205590695142746, -0.132064089179039, -0.08378593623638153, -0.06311982870101929, 0.04079124331474304, -0.06086406856775284, -0.04389605298638344, -0.0252691637724638, 0.06807628273963928, -0.05033986642956734, -0.03770650923252106, -0.0341167077422142, 0.05519256368279457, -0.08224061131477356, 0.11272884905338287, 0.10504540801048279, 0.051315564662218094, -0.12324436008930206, 0.08548370003700256, 0.017429765313863754, 0.013455528765916824, -0.0625137910246849, -0.047298770397901535, -0.10361413657665253, -0.14566485583782196, 0.12918496131896973, 0.025501171126961708, 0.04504096880555153, -0.029690176248550415, -0.1353205442428589, -0.0037216730415821075, 0.0364091619849205, -0.1091139167547226, -0.019732380285859108, -0.003809327259659767, 0.003598954528570175, 0.02463369071483612, -0.02555319294333458, 0.022478748112916946, -0.0693085566163063, -0.010484673082828522, -0.028317727148532867, 0.05288681387901306, -0.11131183803081512, -0.08149251341819763, 0.09779083728790283, 0.11143369972705841, 0.024163665249943733, 0.0455477200448513, -0.002457748167216778, 0.11726295948028564, -0.009895477443933487, -0.04306068271398544, -0.06196998432278633, -0.07944057881832123, -0.06676188111305237, 0.18997272849082947, -0.07767431437969208, -0.07715968787670135, 0.0923176258802414, 0.03751292824745178, 0.06131722405552864, -0.048136547207832336, 0.11877232789993286, 0.03552355617284775, -0.1516362428665161, 0.07661301642656326, -0.0016023926436901093, -0.014937098138034344, -0.2033555656671524, 0.0458158515393734, -0.07753713428974152, 0.01166729349642992, 0.028220970183610916, 0.013083514757454395, -0.06816744804382324, -0.009999038651585579, 0.15369963645935059, -0.07365494221448898, 0.012203488498926163, 0.08172844350337982, -0.0760115310549736, -9.505577762574825e-33, -0.04971502721309662, 0.0422106496989727, 0.02772044576704502, -0.13121861219406128, -0.08198811858892441, 0.11221957951784134, 0.10278133302927017, -0.2526107430458069, 0.020480599254369736, -0.103745236992836, 0.04718375951051712, 0.034768760204315186, -0.10808064043521881, -0.06706002354621887, -0.16445812582969666, 0.17218142747879028, 0.0031359968706965446, -0.052062876522541046, -0.12537436187267303, -0.013417030684649944, 0.07716404646635056, 0.1857435703277588, -0.17871421575546265, 0.018977254629135132, -0.00926422979682684, 0.07748129218816757, 0.05019895359873772, 0.15364429354667664, 0.02950240671634674, -0.034865766763687134, -0.06398557126522064, 0.07868260145187378, -0.19050206243991852, -0.05986487865447998, 0.008722277358174324, 0.01915132999420166, 0.02862761728465557, -0.11719538271427155, 0.06051249802112579, -0.18227353692054749, 0.02476842701435089, 0.019431158900260925, -0.12601983547210693, 0.01725587248802185, 0.08728017657995224, 0.1369592249393463, 0.015495487488806248, 0.027245020493865013, 0.05262847989797592, 0.11131232976913452, -0.05735931545495987, 0.06215250864624977, -0.05118776857852936, -0.019944600760936737, 0.020306991413235664, -0.005367796868085861, -0.03419402614235878, -0.009827329777181149, -0.12558019161224365, 0.052760593593120575, -0.0011655604466795921, 0.06383031606674194, 0.09119100868701935, 0.039493393152952194, 0.10808375477790833, 0.007166443858295679, 0.09001901745796204, 0.047574855387210846, 0.0774664655327797, 0.023311695083975792, -0.11827652901411057, 0.05208869278430939, 0.06448986381292343, -0.11958997696638107, -0.026011712849140167, 0.06348320841789246, -0.10329672694206238, -0.14752094447612762, -0.21064671874046326, -0.09447076916694641, 0.043958745896816254, -0.027780648320913315, 0.12195530533790588, 0.05962354317307472, 0.01787233166396618, 0.047457918524742126, 0.025729503482580185, 0.06184626743197441, 0.06675156950950623, 0.028298819437623024, -0.13873016834259033, -0.1518549621105194, -0.12296877056360245, 0.08032889664173126, -0.0029792380519211292, -9.985846816107369e-08, 0.12403230369091034, -0.06528446078300476, -0.0013637356460094452, -0.15520940721035004, -0.037198588252067566, 0.08083537220954895, -0.18674248456954956, 0.09994905441999435, 0.02148110419511795, 0.1267644762992859, 0.01670079678297043, 0.08323855698108673, -0.05138515308499336, 0.01435431744903326, -0.09368043392896652, 0.01302103791385889, -0.09314761310815811, 0.01403727289289236, -0.05685185641050339, -0.08835483342409134, -0.11877559870481491, -0.04338469356298447, 0.008277326822280884, 0.03525650501251221, 0.04920957610011101, -0.09367837011814117, 0.03770723566412926, 0.16669420897960663, -0.005462802946567535, -0.10544587671756744, -0.05538564175367355, -0.04900147765874863, 0.0679565966129303, 0.05353382229804993, -0.0005137939006090164, -0.14166489243507385, 0.030163094401359558, 0.035205963999032974, 0.014954140409827232, 0.14794626832008362, 0.0870325043797493, 0.15670618414878845, -0.04893629997968674, 0.06381058692932129, -0.04208974540233612, -0.10017816722393036, -0.025310039520263672, 0.08003101497888565, 0.10092590749263763, -0.05130532383918762, -0.028147080913186073, 0.016645953059196472, -0.07498957216739655, -0.045704904943704605, -0.027144568040966988, 0.152215838432312, -0.05212481692433357, -0.014929166063666344, 0.000512298196554184, 0.04101907089352608, -0.002208906225860119, -0.10644783079624176, 0.14721331000328064, -0.08418795466423035], "changes": {"1wk": -9.12453517194537}}, {"text": "PREMIUM Cogent Biosciences Reports Updated Results From Trial of Bezuclastinib MT Newswires Mon, Dec 9, 2024, 3:56 PM 1 min read Cogent Biosciences (COGT) reported updated results Monday from the open-label extension portion of t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2024-12-09T12:56:36+00:00", "sentiment": {"score": 0.029136525467038155, "confidence": 0.04466863349080086, "probabilities": {"positive": 0.04466863349080086, "negative": 0.015532108023762703, "neutral": 0.9397993087768555}}, "embedding": [-0.20406797528266907, -0.02320505678653717, 0.018037686124444008, 0.06927024573087692, 0.1790330410003662, 0.04962081462144852, -0.0990220308303833, 0.16694141924381256, -0.09389388561248779, 0.052541334182024, 0.08157554268836975, 0.049622662365436554, -0.05965634435415268, 0.04683619365096092, -0.05281756445765495, -0.022145221009850502, 0.11088888347148895, -0.1269966959953308, 0.09336185455322266, -0.13374650478363037, -0.03583797439932823, 0.08372705429792404, 0.15142673254013062, 0.01607048325240612, 0.015300260856747627, -0.038597360253334045, -0.2842671573162079, -0.06430204212665558, 0.05484272539615631, -0.06130746379494667, -0.07790679484605789, 0.06155085936188698, 0.11163274198770523, -0.14605079591274261, 0.04721156880259514, -0.09630109369754791, 0.021863188594579697, -0.10999719053506851, -0.011843880638480186, 0.11641955375671387, 0.08849164098501205, -0.055296994745731354, -0.09150692820549011, 0.1324009895324707, -0.015076922252774239, -0.13564549386501312, -0.0906740352511406, -0.10206186771392822, -0.037660397589206696, 0.15534701943397522, -0.10622676461935043, -0.24604366719722748, -0.04516510292887688, -0.07311072945594788, -0.06775949150323868, -0.0008236005669459701, -0.17131315171718597, -0.07382301986217499, -0.03652077540755272, -0.07723577320575714, 0.10192088037729263, -0.08240500837564468, -0.1828422248363495, 0.10772427916526794, 0.08520613610744476, 0.18163873255252838, -0.04913672059774399, 0.13920161128044128, 0.062273912131786346, -0.25146427750587463, 0.06265091150999069, 0.012040052562952042, 0.1059521809220314, 0.12933441996574402, 0.05655314028263092, 0.1936812847852707, 0.08559079468250275, -0.05690215900540352, 0.06711854785680771, -0.1494022011756897, -0.11707354336977005, -0.12906086444854736, 0.04080471023917198, -0.03920489922165871, 0.15135198831558228, -0.015967587009072304, -0.0033625548239797354, 0.0825376957654953, -0.04385770857334137, -0.03842360898852348, 0.2313942164182663, -0.024935433641076088, 0.04284723848104477, 0.0848524272441864, -0.2611274719238281, 0.052646804600954056, -0.19755041599273682, -0.0046330401673913, -0.009168116375803947, -0.036647770553827286, -0.03748590499162674, 0.01857931725680828, -0.10106730461120605, 0.041493289172649384, 0.002161215990781784, -0.10436679422855377, 0.10457967221736908, 0.16489440202713013, 0.19794490933418274, 0.14364483952522278, -0.03710297867655754, 0.11621873825788498, 0.08657333254814148, -0.09369160979986191, -0.07542071491479874, 0.1841995120048523, -0.05293627083301544, 0.06965364515781403, 0.16243606805801392, -0.027417361736297607, 0.11561405658721924, 0.04385164752602577, -0.11211469024419785, -0.18146342039108276, 0.10447445511817932, 0.08404456079006195, -0.007272092625498772, 1.9120676333815763e-32, -0.0006710029556415975, 0.15223035216331482, 0.10800432413816452, 0.02423097938299179, -0.06420350074768066, -0.010698514059185982, -0.09470285475254059, -0.17233027517795563, -0.14217035472393036, -0.07751806080341339, -0.21408239006996155, 0.22582055628299713, -0.05192705988883972, 0.07379334419965744, -0.2399168163537979, -0.14512446522712708, -0.06263750046491623, 0.2145712822675705, 0.07219435274600983, 0.06293906271457672, 0.022108253091573715, 0.0779624730348587, -0.048478107899427414, -0.030511433258652687, 0.005751998629420996, -0.01545244362205267, -0.022426744922995567, 0.014113129116594791, 0.07182217389345169, 0.11371839791536331, -0.1634492576122284, 0.03602956607937813, 0.049530722200870514, 0.08983561396598816, -0.07694325596094131, 0.08367783576250076, -0.06674718111753464, -0.1498708426952362, 0.03811875358223915, -0.05085049197077751, 0.09905706346035004, 0.018513113260269165, -0.079903244972229, -0.06276381760835648, 0.050835564732551575, -0.052901942282915115, -0.13521097600460052, -0.03413752093911171, 0.11493632942438126, -0.07948916405439377, -0.1386914849281311, 0.09964841604232788, -0.16843213140964508, 0.10316450893878937, -0.10718728601932526, 0.20016120374202728, -0.03998261317610741, -0.06045261770486832, 0.16455784440040588, 0.010005752556025982, 0.24460062384605408, 0.11194188892841339, 0.05647454410791397, -0.02899518609046936, 0.032227206975221634, 0.06889251619577408, -0.08630836009979248, -0.10123264789581299, -0.029230892658233643, 0.1845768541097641, -0.02359878458082676, -0.10468117147684097, -0.018104873597621918, 0.07468383014202118, 0.02599944919347763, -0.003331843763589859, -0.037524569779634476, 0.0019438889576122165, 0.027905460447072983, 0.026244159787893295, 0.15153762698173523, -0.0878206193447113, -0.049122124910354614, 0.03240159526467323, 0.07020857185125351, 0.11776648461818695, -0.03135741129517555, 0.0003088209487032145, 0.09952068328857422, -0.019077040255069733, 0.13016662001609802, 0.017521096393465996, -0.0865563228726387, 0.06531859189271927, -0.21410450339317322, -1.6156505697744127e-32, -0.18152225017547607, -0.004995021969079971, 0.028592973947525024, -0.0975331962108612, -0.15556935966014862, 0.010025464929640293, 0.012070666998624802, 0.03859289735555649, 0.13712097704410553, 0.10736032575368881, 0.24026300013065338, -0.019199348986148834, -0.13292637467384338, -0.11087901145219803, 0.008954586461186409, 0.11596889793872833, 0.04468902572989464, -0.11884079873561859, -0.15913118422031403, 0.04345384240150452, -0.04224860295653343, 0.1356857866048813, -0.155299574136734, 0.10477137565612793, -0.014585819095373154, 0.07480490207672119, 0.16512992978096008, 0.13984480500221252, 0.14668872952461243, -0.0903504341840744, -0.05722243711352348, -0.08445728570222855, -0.19826996326446533, -0.06593839079141617, 0.0255725160241127, 0.02697121351957321, 0.2080395668745041, -0.01805409975349903, -0.04059337452054024, -0.09609057754278183, 0.05368826538324356, -0.08681038022041321, -0.1276259422302246, -0.007260599173605442, 0.11943233013153076, 0.009261738508939743, -0.11649397015571594, -0.07657671719789505, 0.04165128991007805, 0.13213256001472473, 0.00011428452125983313, 0.036523621529340744, 0.003642749274149537, -0.03338051587343216, -0.06785188615322113, -0.08763529360294342, 0.03163106366991997, -0.03653983771800995, -0.09450515359640121, 0.026780785992741585, 0.06722655892372131, 0.24624520540237427, -0.16049401462078094, -0.08347450941801071, 0.12284138798713684, 0.07907010614871979, 0.09125243127346039, -0.015058331191539764, 0.01498800702393055, 0.027809737250208855, -0.09627242386341095, 0.04330984875559807, -0.06112362816929817, -0.33159691095352173, -0.05327634513378143, 0.1540563851594925, -0.09274096041917801, -0.10051386058330536, -0.2029859572649002, -0.027759451419115067, -0.00040986205567605793, -0.06636173278093338, 0.16452381014823914, 0.044433269649744034, -0.0005206285277381539, -0.05732240155339241, 0.04471103847026825, 0.008710048161447048, -0.0010344627080485225, 0.1280726045370102, -0.18847675621509552, -0.12981532514095306, -0.20879586040973663, 0.215622678399086, 0.08821121603250504, -1.0019149954132445e-07, 0.07588179409503937, -0.039764177054166794, 0.046236589550971985, 0.07755541801452637, 0.052549153566360474, 0.09212660044431686, -0.19753265380859375, -0.0250202976167202, -0.013995678164064884, 0.14157551527023315, -0.0641099065542221, -0.01638767495751381, -0.01592308096587658, 0.0875534638762474, -0.06502304971218109, -0.009841330349445343, -0.03553082421422005, 0.007324201054871082, -0.02154572121798992, -0.1779426485300064, -0.13865849375724792, 0.09444581717252731, 0.23184466361999512, -0.13413603603839874, 0.023715583607554436, -0.0023124604485929012, -0.05795443430542946, 0.11971113830804825, 0.09998162090778351, -0.12017382681369781, -0.06036316603422165, 0.08203352987766266, -0.02915135584771633, 0.035400692373514175, 0.03209792077541351, -0.037466250360012054, 0.07269970327615738, 0.08679945021867752, -0.007605839986354113, 0.18948012590408325, 0.07230539619922638, -0.003175619523972273, -0.04126477986574173, 0.18799333274364471, -0.005911651533097029, -0.09014245122671127, 0.008660182356834412, -0.05672670528292656, 0.17437757551670074, -0.04211001470685005, 0.04025799036026001, -0.1253620833158493, -0.0093829445540905, -0.059245865792036057, 0.013900334015488625, 0.08745791763067245, -0.0033756166230887175, -0.15303286910057068, -0.08341372758150101, 0.0938667580485344, 0.1504388153553009, -0.3549821972846985, 0.18041694164276123, -0.04235014319419861], "changes": {"1wk": -15.7187222933944, "1mo": -14.684592193283253}}, {"text": "Why Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? Laiba Immad Wed, Dec 4, 2024, 9:05 PM 5 min read We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds . In this article, we are going to take a look at where Cogent Biosciences, Inc. (NASDAQ:COGT) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of Biotechnology The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance. Advances in fields like gene editing, sequencing, personalized medicine, and artificial intelligence are making new techniques possible, while the aging population and growing healthcare demands are driving a robust market for new treatments. According to a report by McKinsey & Company, venture capital firms made approximately $52 billion in global investments in therapeutic-focused biotech companies between 2019 and 2021. Two-thirds of this sum was given to platform-tech start-up companies. Despite its growth, many biotech companies have faced challenges in turbulent markets, taking drastic measures such as cutting programs and implementing significant layoffs to conserve cash. While recent rate cuts could encourage the revival of scientific projects, analysts like Jared Holz note the difficulty of gauging their impact. Holz also highlighted a shift in market dynamics, observing that biotech's performance increasingly correlates with small-cap equities. If small-cap stocks trade well, biotech is likely to follow, though stagnation could occur if momentum fades. Notably, the idea of interest rates predicting biotech success is relatively new, emerging only after the pandemic, which reshaped the industry by driving substantial investment into therapeutic-focused companies. With innovative treatments, biotech businesses are revolutionizing healthcare by tackling important unmet medical needs. Establishing the National Bioeconomy Board as a component of Biden's Investing in America agenda is a significant breakthrough. It seeks to maximize biotechnology's economic potential in the United States. Furthermore, policy suggestions to expedite the approval process for biotechnology goods are being developed by the National Security Commission on Emerging Biotechnology. More academics will be able to use biotechnology for agricultural purposes if entry obstacles are reduced, which will benefit American farmers and increase food security. It is anticipated that these initiatives will open up new markets. Pharmaceuticals as Defensive Investments and the 2024 Healthcare Market Outlook This year (2024) started strongly for the biotechnology sector due to a rise in mergers and acquisitions as well as anticipations of falling interest rates. Therefore, estimates suggest that the worldwide biotechnology market might increase at a compound annual growth rate (CAGR) of around 14% from 2024 to 2033, reaching an astonishing $5.7 trillion. The market for agricultural biotechnology is also expected to develop at a 7.9% compound annual growth rate (CAGR) and reach $232 billion by 2032. Story Continues But even with the market's potential, investing in biotech companies still carries a number of serious dangers. Bankruptcy may result from failing to satisfy clinical trial endpoints or obtain adequate finance before a product launch. In the biotech industry, where drug development usually takes more than ten years and has an estimated failure rate of about 90%, the danger of failure is very substantial. Hence, biotech stocks are often considered \u201chigh-risk, high-reward\u201d investments due to their upside potential coupled with significant risks Our Methodology In our methodology, we identified the top small-cap biotech stocks with significant growth potential, ranked according to their total hedge fund holdings as of Q2 2024. Our selection process began by filtering companies with a small market capitalization. Next, we reviewed analyst recommendations, focusing on stocks with strong bullish sentiment and high institutional ownership. Finally, we ranked these companies based on the number of hedge funds holding their shares as of Q2 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). A group of scientists in a laboratory researching a sophisticated biotechnology drug. Cogent Biosciences, Inc. (NASDAQ: COGT ) Number of Hedge Fund Holdings: 31 Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company focused on developing precision therapies for genetically defined diseases. At its core, the company designs and develops small molecule therapeutics to treat rare conditions with significant unmet medical needs. Cogent Biosciences, Inc. (NASDAQ:COGT) primary focus is on creating treatments for diseases driven by genetic mutations, particularly in oncology. A major catalyst for the company is the advancement of its clinical trials, particularly the SUMMIT and PEAK studies. Cogent Biosciences, Inc. (NASDAQ:COGT) recently announced that its Phase 3 PEAK trial in patients with Gastrointestinal Stromal Tumors (GIST) has completed enrollment and advanced past the interim futility analysis. This progress suggests that bezuclastinib, the company's lead candidate, is showing promise in treating GIST. Additionally, the corporation's SUMMIT trial for Non-Advanced Systemic Mastocytosis (NonAdvSM) is on track, with positive data reported from Part 1b of the study. A significant challenge for Cogent Biosciences, Inc. (NASDAQ:COGT) is the competitive nature of the biotech industry, particularly in the development of treatments for rare diseases. For instance, Blueprint Medicines has already secured approval for Ayvakit in the non-AdvSM market, giving them a first-mover advantage. The company's bezuclastinib must demonstrate superiority to existing treatments to capture market share, which adds pressure to their clinical trial outcomes. As of Q3 2024, 31 hedge fund holders held stakes in the company with Soleus Capital being the largest stakeholder as tracked by the Insider Monkey database. Street analysts hold a consensus Strong Buy rating on the stock. With an upside potential of over 58%, COGT is one of the best biotech stocks on our list. Overall COGT ranks 6th on our list of the best small-cap biotech stocks with massive potential according to hedge funds. While we acknowledge the potential of COGT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than COGT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2024-12-04T18:05:15+00:00", "sentiment": {"score": 0.6427693124860525, "confidence": 0.6609389185905457, "probabilities": {"positive": 0.6609389185905457, "negative": 0.01816960610449314, "neutral": 0.32089146971702576}}, "embedding": [0.047022655606269836, -0.1359926164150238, 0.022687112912535667, -0.07824162393808365, 0.10815418511629105, 0.007807683199644089, -0.04386967420578003, 0.10945781320333481, 0.09650064259767532, 0.10126566141843796, -0.12235423177480698, 0.10078178346157074, -0.10826398432254791, 0.02026103064417839, -0.14580217003822327, -0.02379709482192993, -0.08586686849594116, -0.006454335525631905, -0.08651368319988251, 0.1008356362581253, -0.0042283795773983, 0.030053259804844856, 0.03805232420563698, 0.04832244664430618, -0.008186059072613716, -0.05576352775096893, -0.050773948431015015, -0.11299081146717072, -0.2519475221633911, -0.005544398911297321, 0.08543717116117477, 0.13782502710819244, 0.04263557121157646, -0.042273953557014465, 0.019618229940533638, 0.10055118054151535, -0.07585498690605164, 0.05835926532745361, 0.1301971673965454, 0.020062871277332306, 0.031120210886001587, -0.11519308388233185, -0.11594809591770172, 0.09269129484891891, 0.09366820007562637, -0.13154903054237366, -0.017242535948753357, -0.07551109790802002, 0.04339727386832237, -0.048474833369255066, -0.21448826789855957, -0.17137962579727173, 0.002442360855638981, -0.08237756788730621, -0.02602653205394745, -0.02483908087015152, -0.030450111255049706, -0.04107528179883957, 0.027712246403098106, 0.04021681100130081, 0.09111328423023224, -0.11542484909296036, 0.09382899850606918, -0.027262967079877853, 0.11770576238632202, -0.07323704659938812, 0.09837818145751953, 0.10452821850776672, -0.044432032853364944, 0.05086265876889229, 0.16058078408241272, -0.06674551218748093, -0.09225430339574814, 0.08175259828567505, -0.06089349836111069, 0.12449883669614792, 0.07085677981376648, 0.24065516889095306, 0.22235962748527527, -0.08059953153133392, 0.05275201052427292, -0.08862301707267761, 0.010061179287731647, -0.04435313493013382, -0.16073371469974518, 0.00600535050034523, 0.042425088584423065, 0.06607315689325333, 0.08548639714717865, 0.015883060172200203, -0.02603060007095337, -0.05356776714324951, 0.07740355283021927, 0.04546666890382767, 0.06604932248592377, -0.042344093322753906, -0.04205849766731262, -0.006850002333521843, 0.04519879072904587, -0.00617658207193017, 0.03690195456147194, -0.01969411037862301, -0.034767936915159225, 0.05860665813088417, -0.03016696497797966, -0.0847662091255188, -0.011993534862995148, -0.06423057615756989, 0.15819792449474335, 0.11163286864757538, -0.08947910368442535, 0.14332666993141174, -0.07643584907054901, 0.07877759635448456, -0.09792910516262054, 0.17143183946609497, -0.0044440897181630135, -0.023333527147769928, 0.15683868527412415, 0.04267508164048195, 0.05696257948875427, 0.05681738257408142, -0.07212591916322708, -0.19426366686820984, -0.09968864917755127, 0.09589081257581711, -0.16751302778720856, 8.905786178171569e-33, -0.03141794353723526, 0.07531235367059708, 0.035715483129024506, 0.02712772600352764, -0.09575697779655457, -0.04815595597028732, -0.022833537310361862, -0.049709707498550415, -0.156975656747818, -0.09065812826156616, -0.14857718348503113, 0.11071216315031052, -0.033851489424705505, 0.09690223634243011, -0.013969797641038895, -0.19666758179664612, -0.0332765132188797, 0.06274336576461792, 0.03716064989566803, -0.051999665796756744, -0.11265690624713898, 0.0072792572900652885, -0.08077467978000641, 0.05972512066364288, 0.010700546205043793, -0.17432650923728943, -0.1010822057723999, -0.03212490305304527, 0.06573576480150223, 0.07633563876152039, -0.10756899416446686, 0.09620723128318787, -0.005569642409682274, -0.06637220084667206, -0.022661924362182617, -0.10058058798313141, -0.08588847517967224, -0.1256980001926422, 0.09070578962564468, 0.11124390363693237, -0.07442440092563629, 0.10954427719116211, -0.077596515417099, -0.04487822949886322, 0.03743331879377365, 0.05740584433078766, -0.002589245792478323, 0.05035378038883209, -0.07649625837802887, 0.00838208943605423, -0.1022588312625885, 0.1159239262342453, 0.06425945460796356, -0.07146386802196503, 0.0465870164334774, -0.006466190330684185, -0.1748521327972412, -0.15238986909389496, 0.00223758677020669, -0.0005280999466776848, -0.0311020165681839, 0.07369725406169891, -0.001752613577991724, 0.13222377002239227, -0.08485222607851028, 0.19954219460487366, 0.09924754500389099, 0.12779751420021057, -0.06573449075222015, 0.2497556209564209, 0.032084908336400986, -0.09779366850852966, -0.05627298355102539, -0.026981741189956665, 0.02376272901892662, -0.04347545653581619, -0.008032742887735367, 0.05186368525028229, -0.0682375505566597, 0.06363608688116074, 0.0848890095949173, 0.025529980659484863, -0.1649678349494934, -0.012367590330541134, -0.007759004831314087, 0.01446893997490406, 0.012032510712742805, 0.1140437051653862, 0.012907861731946468, -0.024797387421131134, -0.102084219455719, -0.07145293802022934, 0.00935666449368, 0.14691266417503357, -0.038729071617126465, -1.0846978447336293e-32, -0.043018683791160583, -0.10486666858196259, -0.006167037412524223, 0.04084230959415436, -0.008291887119412422, 0.02801917865872383, 0.09890353679656982, -0.17798952758312225, 0.03266787528991699, -0.05593297258019447, 0.0018443204462528229, 0.05169147625565529, 0.014764768071472645, -0.006331328302621841, -0.14634937047958374, 0.029846593737602234, -0.04561654105782509, -0.08199772238731384, 0.03313257172703743, -0.005405642092227936, 0.08310540020465851, 0.05468205362558365, -0.14530284702777863, 0.07187798619270325, 0.017995715141296387, 0.08311543613672256, -0.11173427104949951, 0.11849582940340042, 0.03981544449925423, -0.08157860487699509, -0.09831985831260681, 0.0324283204972744, -0.21572478115558624, 0.12476931512355804, -0.06691669672727585, 0.06871597468852997, 0.030467048287391663, -0.15221258997917175, 0.07329260557889938, -0.040057577192783356, 0.10085754096508026, -0.03773733228445053, -0.07927132397890091, 0.020058829337358475, 0.025545934215188026, -0.07378015667200089, -0.03443026915192604, 0.08172550052404404, 0.141160786151886, 0.03533032536506653, -0.02694815769791603, 0.14927127957344055, 0.0470796637237072, -0.037604477256536484, -0.15484385192394257, 0.008578990586102009, 0.05823289602994919, 0.029012737795710564, -0.13147729635238647, 0.061355963349342346, 0.036458536982536316, 0.06776205450296402, 0.023790886625647545, 0.05003011226654053, -0.07603557407855988, -0.05589310824871063, 0.09963695704936981, 0.01391268614679575, -0.0720781683921814, -0.1095193549990654, 0.03266184404492378, -0.007133082021027803, 0.06534021347761154, -0.06924418359994888, -0.04842744767665863, 0.19791752099990845, -0.053590480238199234, -0.13806410133838654, -0.1312112659215927, 0.06424111872911453, 0.080245241522789, -0.015618603676557541, 0.09847255051136017, -0.07406048476696014, -0.019464807584881783, 0.11642773449420929, -0.048160701990127563, -0.030234873294830322, -0.12095372378826141, 0.003941750153899193, -0.1477489471435547, -0.21344038844108582, -0.03219621628522873, 0.08442308008670807, -0.04910686984658241, -1.0033503627937534e-07, 0.18440024554729462, -0.09899711608886719, 0.11094369739294052, -0.10599604994058609, 0.08103364706039429, -0.020515622571110725, -0.15989094972610474, 0.09536132216453552, 0.11347068846225739, 0.16978436708450317, 0.028260868042707443, 0.18039609491825104, -0.14476513862609863, 0.20725196599960327, -0.08057259023189545, 0.07238250970840454, -0.1703040897846222, 0.03208101540803909, -0.03716834634542465, -0.03238188847899437, -0.03510440140962601, 0.10275284200906754, -0.01227039285004139, 0.03769098222255707, 0.042680539190769196, -0.07242685556411743, 0.02449885755777359, 0.05551033467054367, -0.016227055341005325, 0.022990521043539047, -0.01150430552661419, -0.04905427619814873, 0.06269624084234238, 0.05045447498559952, -0.025917859748005867, -0.06533104181289673, 0.043160662055015564, 0.027896761894226074, -0.022060785442590714, 0.04116438329219818, 0.006225861608982086, 0.016461074352264404, -0.05049525201320648, -0.0265677347779274, -0.025661304593086243, -0.13018116354942322, -0.06851151585578918, 0.12025292217731476, 0.09622928500175476, -0.10028576850891113, 0.07695839554071426, 0.00756507832556963, 0.014265203848481178, 0.037274520844221115, 0.03015291504561901, 0.15896481275558472, -0.07042810320854187, -0.02381095290184021, -0.08656580746173859, -0.03353797271847725, -0.00115196593105793, -0.26999032497406006, 0.17131930589675903, -0.004398580640554428], "changes": {"1wk": 0.6514703514460695, "1mo": -14.440824301816694}}, {"text": "PREMIUM Needham Downgrades Cogent Biosciences to Hold From Buy MT Newswires Wed, Dec 11, 2024, 3:57 PM Cogent Biosciences (COGT) has an average rating of overweight and mean price target of $16.60, accor PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2024-12-11T12:57:45+00:00", "sentiment": {"score": 0.03503762651234865, "confidence": 0.04986075684428215, "probabilities": {"positive": 0.04986075684428215, "negative": 0.014823130331933498, "neutral": 0.9353161454200745}}, "embedding": [-0.16539788246154785, -0.022660385817289352, 0.027996858581900597, 0.044480226933956146, 0.09805107116699219, -0.03340006619691849, -0.08610597997903824, 0.13383471965789795, -0.15993894636631012, 0.08314362913370132, 0.03433392569422722, -0.13441650569438934, -0.14437070488929749, 0.012486523017287254, -0.09739314019680023, -0.09997714310884476, 0.1456591635942459, -0.17215697467327118, 0.050547901540994644, 0.003048829734325409, -0.0893382579088211, 0.12187261134386063, -0.08009593188762665, 0.045241162180900574, 0.019363123923540115, -0.11975637823343277, -0.2005649358034134, -0.06325292587280273, 0.06956589221954346, 0.019953962415456772, -0.05331461504101753, 0.003620160510763526, 0.05613863095641136, -0.04391730576753616, -0.03818992152810097, 0.04610780254006386, 0.07042700052261353, -0.22772477567195892, -0.0325683131814003, 0.16963618993759155, -0.021765876561403275, 0.03529981151223183, -0.1222609356045723, 0.09318393468856812, -0.07342924922704697, -0.1341310739517212, -0.07091327756643295, -0.027920877560973167, 0.13777711987495422, 0.1509469449520111, -0.13086636364459991, -0.156722292304039, 0.02699257992208004, -0.12432321161031723, -0.0652170479297638, 0.0035313169937580824, -0.15362323820590973, -0.042909570038318634, -0.06501548737287521, -0.13852137327194214, 0.12538649141788483, -0.19884447753429413, -0.04944184422492981, 0.07639431208372116, 0.15223662555217743, 0.05918898433446884, 0.032138269394636154, 0.030525146052241325, 0.12905514240264893, -0.06157128885388374, 0.0008852077298797667, -0.026808349415659904, 0.014473499730229378, 0.013409496285021305, 0.053109586238861084, 0.2592760920524597, 0.04123447835445404, -0.21163097023963928, 0.10755284130573273, -0.1252523809671402, -0.05268856883049011, -0.06974457949399948, 0.06450627744197845, -0.08991747349500656, 0.13711318373680115, -0.16790662705898285, 0.10011769086122513, 0.10964904725551605, -0.012580188922584057, -0.04368571937084198, 0.177181214094162, -0.09785927087068558, 0.04843592271208763, 0.07726213335990906, -0.13028527796268463, 0.13497018814086914, -0.16032420098781586, -0.03725461661815643, -0.13324704766273499, -0.100212961435318, -0.07577302306890488, 0.0964520201086998, 0.02010413631796837, 0.15030469000339508, -0.04208910092711449, -0.21876001358032227, 0.08734472841024399, 0.18926218152046204, 0.22229255735874176, 0.195845827460289, -0.10439769178628922, 0.17527587711811066, 0.06786692887544632, -0.046270404011011124, -0.04170430824160576, 0.2250320166349411, -0.04081284999847412, -0.010510713793337345, 0.10500025004148483, -0.014567950740456581, 0.016311297193169594, -0.026451407000422478, -0.17360617220401764, -0.10933137685060501, 0.008573302067816257, -0.06614997237920761, -0.03489707410335541, 1.3593597405165372e-32, 0.006861319299787283, 0.11332619190216064, 0.01734616607427597, -0.1254526823759079, -0.14818713068962097, -0.04850513115525246, -0.07638073712587357, -0.05576471984386444, -0.09387829899787903, -0.06485086679458618, -0.042535923421382904, 0.20028594136238098, -0.08095049858093262, 0.08032859861850739, -0.13791006803512573, -0.20904293656349182, -0.028565384447574615, 0.13718152046203613, 0.16254372894763947, 0.04885377734899521, -0.07596822082996368, 0.03465570881962776, -0.07855336368083954, 0.02583216316998005, -0.036938801407814026, -0.007857227697968483, -0.01966792903840542, 0.03185054287314415, 0.10491989552974701, 0.07066944241523743, -0.07310361415147781, -0.05507117509841919, 0.07852663844823837, -0.010944966226816177, -0.12511806190013885, -0.014937330037355423, -0.11505281925201416, -0.10451868176460266, 0.022625362500548363, -0.09754371643066406, 0.0917477235198021, 0.0650303065776825, -0.01486179605126381, -0.05563805624842644, -0.00616065738722682, -0.028029603883624077, 0.08677951246500015, -0.11723195016384125, -0.04853173345327377, -0.03713061660528183, -0.18331807851791382, 0.11248130351305008, -0.1793162077665329, 0.13806326687335968, -0.1513081192970276, 0.01505148783326149, -0.08806940913200378, -0.094553142786026, 0.18349653482437134, 0.010502006858587265, 0.1555134803056717, 0.11731909215450287, 0.12763604521751404, 0.012232775799930096, 0.030402950942516327, -0.015264567919075489, -0.10915278643369675, -0.13093474507331848, -0.13235118985176086, 0.31695520877838135, 0.018322501331567764, -0.1529206782579422, -0.0893939733505249, 0.007963593117892742, 0.0562744066119194, 0.016380852088332176, -0.006823270581662655, -0.06948361545801163, 0.040954042226076126, 0.06945367157459259, -0.000700764125213027, -0.005901714321225882, 0.001117104198783636, -0.07020028680562973, 0.01846127398312092, 0.08493369817733765, -0.08828745037317276, 0.05319682136178017, 0.04774629697203636, -0.03850606456398964, 0.043478675186634064, 0.019674254581332207, -0.12338470667600632, 0.017446231096982956, -0.11584386974573135, -1.451149833205228e-32, -0.14058749377727509, -0.06760688126087189, 0.104149229824543, 0.05769602209329605, -0.09143909066915512, 0.1392795294523239, 0.022970234975218773, -0.07952544838190079, 0.15407678484916687, 0.17766684293746948, 0.14408499002456665, 0.03257741779088974, -0.1807154417037964, -0.015823421999812126, 0.14279226958751678, 0.112162284553051, -0.07485650479793549, -0.06927767395973206, 0.03372854366898537, -0.021422596648335457, 0.0670018121600151, 0.20595602691173553, -0.1383248269557953, 0.18870636820793152, 0.06411883980035782, 0.1626855880022049, 0.03998284041881561, 0.09381535649299622, 0.0710604190826416, -0.09056082367897034, -0.07673713564872742, -0.028360817581415176, -0.13570411503314972, 0.10589032620191574, -0.0487198568880558, -0.002286965725943446, 0.08491486310958862, 0.1840439885854721, -0.11538980901241302, -0.00036606055800803006, 0.14531905949115753, -0.038075946271419525, -0.08581888675689697, -0.059745945036411285, 0.1535414308309555, -0.1418672502040863, 0.013624763116240501, -0.17334319651126862, 0.1545095592737198, 0.15058770775794983, -0.0005021478282287717, 0.01922813057899475, 0.02427065186202526, 0.042838454246520996, -0.12280629575252533, 0.03513951599597931, -0.015040310099720955, 0.03005191870033741, -0.029936611652374268, -0.12389528751373291, 0.09881817549467087, 0.19242435693740845, -0.19130393862724304, -0.03872232139110565, 0.0067335376515984535, 0.15342730283737183, 0.17746511101722717, -0.09534997493028641, -0.03798846900463104, 0.08607272803783417, -0.08919165283441544, 0.06639236211776733, 0.20155885815620422, -0.32569244503974915, -0.029657451435923576, 0.09123100340366364, -0.015949426218867302, -0.03593076393008232, -0.10726723819971085, -0.1274464875459671, -0.020182592794299126, -0.12021680176258087, 0.22750410437583923, -0.026121441274881363, 0.031745489686727524, -0.05224129185080528, -0.03696143627166748, 0.06527890264987946, -0.06718847900629044, 0.25844404101371765, -0.20330241322517395, -0.11846496909856796, -0.007847088389098644, -0.08702640980482101, 0.049399234354496, -1.0004554695797196e-07, 0.16521939635276794, -0.021467657759785652, 0.1257544457912445, 0.03029461018741131, 0.1156962662935257, 0.1361347883939743, -0.15311703085899353, 0.02919367328286171, 0.05454297736287117, 0.257770299911499, -0.02272755093872547, -0.04986463859677315, 0.05344050005078316, 0.07656414061784744, -0.18959322571754456, -0.09363515675067902, -0.12641273438930511, 0.10553556680679321, -0.03665381297469139, -0.11441432684659958, -0.12280945479869843, 0.0185999758541584, 0.1317041516304016, 0.07834260910749435, 0.025201909244060516, 0.13462091982364655, 0.06875662505626678, 0.09386815130710602, 0.05884304270148277, -0.033619869500398636, -0.07923253625631332, 0.12012291699647903, 0.04328646883368492, 0.05708473548293114, 0.0671120285987854, -0.11593654751777649, 0.031654536724090576, 0.14225426316261292, -0.16028732061386108, 0.11285246908664703, -0.037592653185129166, -0.034289345145225525, -0.09563124924898148, 0.08649199455976486, 0.1673182249069214, -0.06563617289066315, -0.16648556292057037, -0.016861967742443085, 0.1035819947719574, -0.01779727078974247, 0.17612574994564056, -0.04988434165716171, -0.02738299034535885, 0.21582329273223877, -0.035434599965810776, -0.029745200648903847, -0.09073735028505325, -0.09312237054109573, -0.2507164776325226, 0.06711724400520325, 0.1380295604467392, -0.37848642468452454, 0.15632785856723785, -0.09848591685295105], "changes": {"1wk": -11.6504943263068, "1mo": -12.51349238192237}}, {"text": "Why Is Cogent Biosciences Stock Trading Higher On Monday? Vandana Singh Mon, Dec 9, 2024, 8:52 PM 2 min read Why Is Cogent Biosciences Stock Trading Higher On Monday? On Sunday, Cogent Biosciences, Inc. (NASDAQ: COGT ) revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis . Non-advanced systemic mastocytosis is\u00a0a rare disease that involves mast cell buildup in tissues and organs . Updated clinical data presented at the American Society of Hematology\u00a0Annual Meeting & Exposition show: 56% mean improvement in Total Symptom Score (TSS) at 24 weeks. 76% of patients demonstrated a>50% reduction from baseline in the MS2D2 Total Symptom Score (TSS), with 88% exceeding a 30% reduction from baseline after 24 weeks. 49% mean improvement in quality of life Total Score at 24 weeks. At 24 weeks of treatment, 31% of patients have already reduced or discontinued best supportive care (BSC) medications. Pharmacodynamic Data: Bezuclastinib showed rapid, deep, and sustained reductions in serum tryptase over 24 weeks of treatment, including: 89% of patients had\u00a0>50% decrease in serum tryptase levels by four weeks of treatment 95% of patients with baseline tryptase \u226520ng/mL achieved <20ng/mL by week 24 84% of patients with baseline serum tryptase\u00a0>11.4ng/ml achieved <11.4ng/mL by week 24 Safety Data As of the data cutoff, August 29, 2024, the median duration of bezuclastinib treatment was 56 weeks for patients in the active arm and 40 weeks for placebo patients who crossed over to the OLE. The majority of treatment-emergent adverse events were low-grade and reversible, with no treatment-related bleeding or cognitive impairment events reported. SUMMIT Enrollment Update Cogent also announced that enrollment in the registration-directed SUMMIT Part 2 study is complete. A total of 179 patients were enrolled and top-line results from the trial are expected in July 2025. Price Action: COGT stock is up 10.60% at $9.83 at the last check on Monday. Read Next: Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Why Is Cogent Biosciences Stock Trading Higher On Monday? originally appeared on Benzinga.com \u00a9 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2024-12-09T17:52:46+00:00", "sentiment": {"score": 0.009555935859680176, "confidence": 0.4011666178703308, "probabilities": {"positive": 0.4011666178703308, "negative": 0.39161068201065063, "neutral": 0.20722274482250214}}, "embedding": [0.05313386768102646, -0.04910745471715927, -0.010209674015641212, 0.05087670683860779, -0.046441495418548584, 0.07159046828746796, -0.1326262354850769, 0.32256436347961426, -0.005910666659474373, 0.1375463306903839, -0.06814931333065033, -0.026408959180116653, -0.0657561719417572, 0.1323426216840744, -0.1082761287689209, -0.028417835012078285, 0.13866335153579712, -0.04698920249938965, -0.04852446913719177, 0.041261229664087296, 0.05561947822570801, 0.01761833019554615, 0.1458233743906021, 0.04758262261748314, -0.007874779403209686, -0.11874933540821075, -0.18268337845802307, -0.07137484103441238, -0.03394095599651337, 0.05992471054196358, -0.0327170230448246, 0.06049995869398117, -0.007367844693362713, -0.07147198915481567, -0.08353690057992935, -0.05715034157037735, -0.05382886156439781, -0.0678362250328064, -0.029383815824985504, -0.009007874876260757, 0.06101249158382416, 0.030853761360049248, -0.08991988748311996, -0.021869348362088203, -0.010363501496613026, -0.1212310791015625, -0.07281702011823654, 0.05415189266204834, 0.03466608747839928, 0.12136255204677582, -0.14811119437217712, -0.15930715203285217, -0.004904179833829403, 0.012547734193503857, -0.026251021772623062, 0.008032869547605515, -0.09815067052841187, -0.053558893501758575, 0.09530571848154068, 0.10982950031757355, -0.03950865566730499, -0.023868640884757042, -0.06858983635902405, 0.050663501024246216, 0.22923795878887177, 0.04333830624818802, -0.07175429165363312, 0.029758956283330917, -0.020206425338983536, -0.012964988127350807, 0.11171317845582962, -0.18118254840373993, 0.04739006608724594, 0.10006347298622131, -0.028322044759988785, 0.08978614211082458, 0.0757790133357048, 0.08829499781131744, -0.0008496572263538837, -0.0424346923828125, -0.11179719120264053, 0.037846639752388, -0.014231388457119465, 0.02565348520874977, 0.023740310221910477, 0.04930182918906212, -0.04309283196926117, 0.20012743771076202, -0.056578829884529114, -0.03586830943822861, 0.24925053119659424, 0.018106769770383835, -0.03831300139427185, 0.016973920166492462, 0.014009516686201096, 0.013159535825252533, -0.09927525371313095, 0.14978377521038055, -0.00898454338312149, -0.07680647820234299, -0.026852693408727646, -0.006759265437722206, -0.1583695411682129, -0.07503271102905273, -0.042818859219551086, -0.04021644964814186, 0.1346757709980011, -0.061950478702783585, -0.006601002998650074, 0.008561360649764538, -0.12343079596757889, 0.07425428181886673, -0.042948633432388306, -0.023826109245419502, -0.07718847692012787, 0.22825798392295837, -0.007336167618632317, 0.07777059078216553, 0.1496639847755432, 0.07474662363529205, 0.15902110934257507, -0.04241788387298584, 0.07287557423114777, -0.1493602991104126, 0.13869275152683258, 0.05996548384428024, 0.017520779743790627, 1.2209153056012668e-32, 0.05908335745334625, 0.01608245074748993, 0.11476871371269226, -0.015525953844189644, -0.09246551990509033, 0.033090636134147644, 0.049160268157720566, -0.1192702203989029, -0.0008385181427001953, -0.021605174988508224, -0.1362590342760086, 0.033417172729969025, 0.04506446421146393, 0.03661748766899109, -0.10025490820407867, -0.12848177552223206, 0.015751365572214127, -0.016634827479720116, -0.08418221771717072, 0.0451677031815052, -0.02250918373465538, 0.07878997921943665, -0.03810804337263107, -0.025021333247423172, -0.13094976544380188, 0.08375000953674316, -0.1047360897064209, 0.010944103822112083, 0.05729597806930542, 0.053643859922885895, -0.024730630218982697, 0.0485595166683197, -0.04128213971853256, -0.07298532128334045, -0.10755212604999542, -0.04472791403532028, -0.015130017884075642, -0.06034446880221367, 0.017827991396188736, -0.05655074119567871, 0.0349126011133194, 0.0793788954615593, -0.09668134152889252, -0.0326838456094265, 0.012039130553603172, -0.15918272733688354, -0.08099915087223053, -0.13945892453193665, 0.003332659602165222, -0.009044703096151352, -0.030151858925819397, -0.06425109505653381, 0.013073105365037918, -0.061406441032886505, -0.12506063282489777, 0.13342192769050598, -0.027535617351531982, -0.02347814291715622, 0.07888002693653107, 0.08047544956207275, 0.08261151611804962, -0.0412365086376667, 0.025312140583992004, 0.10357489436864853, 0.01494449283927679, 0.10543599724769592, -0.0581093467772007, -0.16802361607551575, -0.1346552073955536, 0.07827197760343552, -0.03323975205421448, -0.05231309309601784, 0.10732996463775635, 0.05983073264360428, 0.05414723604917526, 0.015330685302615166, 0.09570058435201645, 0.052911579608917236, -0.06700312346220016, -0.06971009820699692, 0.06727688014507294, -0.06907391548156738, -0.1351926475763321, 0.1250123381614685, 0.09452103823423386, 0.00871338602155447, -0.08731701970100403, 0.03541338071227074, -0.043373435735702515, -0.03468283265829086, 0.08093991130590439, 0.012863414362072945, -0.04940255731344223, 0.031126759946346283, -0.06191931292414665, -1.2820740726226427e-32, -0.04910701513290405, 0.13146209716796875, -0.0434659905731678, -0.12489889562129974, -0.0391240119934082, 0.08242808282375336, 0.0821661427617073, -0.09741266816854477, -0.014997153542935848, -0.10177699476480484, 0.10821335017681122, -0.024997912347316742, -0.06231245771050453, 0.027760833501815796, -0.20639997720718384, 0.19166265428066254, -0.046603500843048096, 0.03691687434911728, -0.059418901801109314, -0.09464158117771149, 0.04867132753133774, 0.18158431351184845, -0.006548047065734863, 0.03061019815504551, 0.05545387417078018, 0.09641879796981812, 0.014792007394134998, 0.1512289047241211, 0.025912802666425705, -0.07376573979854584, 0.0036096470430493355, 0.027262382209300995, -0.19973930716514587, -0.03294115513563156, 0.018425410613417625, 0.011701585724949837, 0.0909445732831955, -0.14685629308223724, -0.035892169922590256, -0.07534414529800415, -0.035821299999952316, 0.04865570366382599, 0.03868043050169945, -0.06693373620510101, 0.15620559453964233, -0.022965747863054276, -0.028086762875318527, -0.08908957242965698, 0.07848353683948517, 0.12685741484165192, -0.07649821788072586, 0.06721697747707367, 0.06622467935085297, 0.060697510838508606, 0.03924790024757385, -0.10683384537696838, 0.07032462954521179, -0.17814233899116516, -0.1634233593940735, -0.05940824747085571, 0.10042083263397217, 0.14099065959453583, -0.03898642957210541, -0.03294941037893295, 0.174019455909729, 0.0943581610918045, 0.10611715912818909, -0.05190567672252655, 0.05632440745830536, -0.07294369488954544, -0.10289964079856873, -0.1874295473098755, -0.025394517928361893, -0.1717386543750763, -0.09254683554172516, 0.14833828806877136, -0.04244501516222954, -0.06402505934238434, -0.12229808419942856, -0.011733734980225563, -0.08870352804660797, -0.07971104979515076, 0.013527198694646358, 0.0587703175842762, 0.008900153450667858, -0.047904759645462036, -0.017722100019454956, -0.005959333851933479, 0.1019468754529953, 0.06898637861013412, -0.16953064501285553, -0.10774220526218414, -0.04378809034824371, 0.0960998386144638, 0.01749425195157528, -1.0085177848395688e-07, 0.07126569747924805, -0.1193636953830719, 0.05231652781367302, -0.0037504839710891247, 0.06757524609565735, 0.051179323345422745, -0.25290346145629883, 0.006036345846951008, -0.02538498118519783, 0.13756680488586426, 0.015439780429005623, 0.037169039249420166, -0.13476184010505676, -0.05868320167064667, -0.052715450525283813, -0.0033872174099087715, 0.05005635693669319, 0.02483241632580757, 0.028879733756184578, -0.038982439786195755, -0.07193395495414734, -0.06708590686321259, 0.1322098672389984, -0.12467879056930542, -0.03570987656712532, 0.061179857701063156, 0.0013713412918150425, 0.2367938756942749, -0.005123973358422518, -0.08420111984014511, -0.004902575630694628, 0.007599812000989914, 0.13299739360809326, 0.055965207517147064, -0.05669046565890312, -0.016756001859903336, 0.06361240148544312, 0.11205055564641953, 0.022899920120835304, 0.1896331012248993, 0.03783239424228668, 0.07167692482471466, -0.010947199538350105, 0.08555464446544647, 0.08308853209018707, -0.10656099021434784, -0.06709699332714081, 0.022836456075310707, 0.18051832914352417, -0.20672278106212616, -0.02439136803150177, -0.014658987522125244, -0.06184279918670654, -0.01657547801733017, -0.03601294755935669, 0.10441173613071442, -0.04956892132759094, 0.04810556024312973, -0.030952230095863342, -0.05510951578617096, 0.06604515016078949, -0.14788958430290222, -0.008841315284371376, -0.023064931854605675], "changes": {"1wk": -14.58117721083303, "1mo": -16.13237236099975}}, {"text": "Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) Cogent Biosciences, Inc. Sun, Dec 8, 2024, 8:00 PM 7 min read In This Article: COGT -3.44% Cogent Biosciences, Inc. 52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of response and median PFS not yet reached Top-line data from APEX Part 2 on-track for mid-2025 Cogent to host investor webcast on Monday, December 9 at 8:00 a.m. ET WALTHAM, Mass. and BOULDER, Colo., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive updated data from Part 1 of the Company\u2019s ongoing Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) at the 66 th American Society of Hematology (ASH 2024) Annual Meeting & Exposition taking place December 7-10, 2024 in San Diego, CA. \u201cBezuclastinib has the potential to transform the treatment landscape for people living with advanced systemic mastocytosis,\u201d said Daniel J. DeAngelo, M.D., Ph.D., Chief of the Division of Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine, Harvard Medical School. \u201cThe impressive clinical data presented today from APEX Part 1 demonstrates a combination of rapid and deep clinical responses, with a safety profile that avoids several of the most concerning side effects for AdvSM patients today.\u201d \u201cWe are excited to share today the updated clinical data from APEX Part 1 studying bezuclastinib in patients with advanced systemic mastocytosis,\u201d said Andrew Robbins, Cogent\u2019s President and Chief Executive Officer. \u201cThese results show the enormous promise that a highly potent, highly selective, non-brain penetrant KIT inhibitor may provide to this patient population. We look forward to completing enrollment in APEX Part 2 and sharing the results from that study in mid-2025.\u201d Patient Demographics APEX is a global, open-label, multi-center, two-part Phase 2 clinical trial in patients with AdvSM evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. Thirty-two patients were treated in Part 1 at one of four dose levels (50 mg BID, 100 mg BID, 200 mg BID or 400 mg QD). Earlier this year, Cogent announced APEX Part 2 would be conducted at the optimized 150mg QD dose, which closely matches the exposure from 100 mg BID dose in APEX Part 1. The median age of patients at study entry was 68 years (ranging from 33-87 years). Patients were enrolled with the following sub-types: seven patients with aggressive systemic mastocytosis (ASM), 23 patients with systemic mastocytosis with associated hematologic neoplasm (SM-AHN), and two patients with mast cell leukemia (MCL). Five patients had received prior avapritinib and 10 patients had received prior midostaurin treatment. Story Continues Clinical Activity Data As of the data cutoff date of October 11, 2024, 32 patients enrolled were evaluated for signs of clinical activity, 27 of whom were mIWG-MRT-ECNM evaluable. Clinical activity analyzed across dose levels and focused on 100 mg BID cohort showed: 52% ORR (CR+CRh+PR+CI) per mIWG-MRT-ECNM criteria, including 61% ORR for TKI-treatment-na\u00efve patients 83% ORR for patients treated at 100 mg BID dose cohort 88% ORR (CR+PR) per pure pathological response (PPR) criteria 100% ORR for patients treated at 100 mg BID dose cohort Median time to achieve response was 2.2 months and median duration of response has not yet been reached Median PFS was not yet reached at median follow-up of 20 months; PFS rate at 24 months was 82% Pharmacodynamic Data Nearly all patients demonstrated a significant improvement in biomarkers associated with disease burden. Patients without post baseline biomarker data were excluded from relevant analyses. 94% of patients achieved \u226550% reduction in serum tryptase levels 100% of patients receiving \u22652 cycles achieved \u226550% reduction 66% of patients achieved reduction of serum tryptase below 20 ng/mL 93% of KITD816V-positive patients achieved \u226550% reduction in KIT D816V variant allele fraction (VAF) 100% of evaluable patients achieved a \u226550% reduction in bone marrow mast cell burden 83% achieved complete clearance of mast cell aggregates by central review Safety Data As of the data cutoff date of October 11, 2024, bezuclastinib continues to demonstrate a differentiated safety and tolerability profile across doses. The majority of hematological adverse events were low grade and reversible. There have been no new treatment related serious adverse events or discontinuations reported since ASH 2023. Due to confounding medical issues, one patient previously reported with DILI has been reassessed and reported as a Grade 4 gamma-glutamyl transferase (GGT) elevation case. Twelve patients required dose reduction, eight of whom were treated at a 400 mg daily dose. Bezuclastinib in Systemic Mastocytosis Cogent is actively enrolling patients into APEX Part 2 which is anticipated to complete enrollment in Q1 2025 with top-line results expected in mid-2025. Cogent will present 24-week follow-up data from patients who participated in the Open Label Extension portion of the ongoing SUMMIT trial on Monday, December 9, 2024 at ASH. SUMMIT is a randomized, double-blind, placebo-controlled, global, multicenter Phase 2 trial evaluating bezuclastinib in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). Webcast Information and ASH Posters Cogent will host a webcast on Monday, December 9, 2024 at 8:00 a.m. ET to discuss updated clinical results from both the APEX and SUMMIT ASH presentations. The live event will be available on the Investors & Media page of Cogent\u2019s website at investors.cogentbio.com . A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.\u00a0The ASH posters will be available to registered conference attendees and will also be in the Posters and Publications section of Cogent\u2019s website at www.cogentbio.com/research . About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2, PI3K\u03b1\u00a0and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com . Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn . Information that may be important to investors will be routinely posted on our website and X . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the expectation for the company to complete enrollment for APEX Part 2 in Q1 2025 and to have top-line data in mid-2025; the potential for bezuclastinib to transform the treatment landscape for people living with AdvSM; and the potential benefit that a highly potent, highly selective, non-brain penetrant KIT inhibitor may provide to patients with AdvSM. The use of words such as, but not limited to, \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"will,\" or \"would\" and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption \"Risk Factors\" in Cogent's most recent Quarterly Report on Form 10-Q filed with the\u00a0SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Contact: Christi Waarich Senior Director, Investor Relations christi.waarich@cogentbio.com 617-830-1653 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2024-12-08T17:00:00+00:00", "sentiment": {"score": 0.7399770310148597, "confidence": 0.748924732208252, "probabilities": {"positive": 0.748924732208252, "negative": 0.008947701193392277, "neutral": 0.24212756752967834}}, "embedding": [-0.0553676076233387, -0.11011672019958496, -0.06700721383094788, -0.013430941849946976, -0.03079553321003914, -0.14242787659168243, -0.1340111494064331, 0.1992001086473465, -0.0016251523047685623, 0.10956107825040817, -0.10965946316719055, -0.009976515546441078, -0.014280905947089195, 0.12467116117477417, -0.1109696626663208, 0.09051541984081268, 0.10953913629055023, -0.007784219458699226, -0.03354509919881821, 0.03071632795035839, 0.048182498663663864, 0.009594198316335678, 0.11370297521352768, 0.043113406747579575, -0.037626463919878006, -0.15836933255195618, -0.18346238136291504, -0.02772238850593567, -0.1331738382577896, -0.011401701718568802, -0.01568664237856865, 0.10340040922164917, 0.02217554859817028, -0.046251602470874786, -0.06977851688861847, 0.0038616377860307693, -0.05060271918773651, -0.09476408362388611, -0.038968201726675034, -0.06104986369609833, 0.06450752913951874, 0.10727809369564056, -0.024420036002993584, 0.0447707362473011, 0.0048269229009747505, -0.14099666476249695, -0.10980887711048126, -0.029114359989762306, 0.02688644826412201, 0.153621643781662, -0.1331518590450287, -0.11836177110671997, -0.043046340346336365, 0.04320769011974335, -0.047888703644275665, 0.02370695024728775, -0.10235084593296051, -0.025975525379180908, 0.0774926170706749, 0.07075664401054382, 0.0048804678954184055, -0.03608638048171997, -0.06846559047698975, 0.020677145570516586, 0.22247740626335144, 0.10150979459285736, -0.009243708103895187, 0.027537446469068527, -0.07094550132751465, -0.04729977250099182, 0.09305107593536377, -0.11977288126945496, -0.0027446099556982517, 0.10352954268455505, -0.02102639526128769, 0.08637858182191849, 0.08409558236598969, 0.1394050270318985, 0.06688600033521652, -0.08994853496551514, -0.03055979311466217, 0.082939013838768, 0.06074145808815956, -0.0247280765324831, 0.02646932378411293, 0.08742973208427429, -0.018502507358789444, 0.23512451350688934, 0.025022270157933235, 0.04083886370062828, 0.13287904858589172, -0.00739665562286973, 0.06869877874851227, 0.06945478916168213, 0.016686977818608284, 0.03850988671183586, 0.0006764447316527367, 0.06563223898410797, -0.03505980223417282, -0.07026561349630356, -0.034629762172698975, 0.007181268185377121, -0.10145474970340729, -0.11745637655258179, 0.038091424852609634, -0.030138373374938965, 0.10480757057666779, 0.01115240529179573, 0.038210488855838776, 0.03966151550412178, -0.02769225463271141, 0.06184115260839462, -0.012560267001390457, -0.027772605419158936, 0.0043217772617936134, 0.16593605279922485, -0.011454401537775993, 0.04223012924194336, 0.19329163432121277, -0.0022712652571499348, 0.1567343920469284, -0.032824527472257614, 0.02849837951362133, -0.16596519947052002, 0.19927197694778442, 0.0991601049900055, -0.10238005965948105, 1.212202614941369e-32, -0.05459558591246605, 0.0894060954451561, 0.16613677144050598, 0.05500011146068573, -0.051804069429636, -0.014045442454516888, 0.05776442587375641, -0.03724061697721481, -0.08930370211601257, -0.06133362650871277, -0.14808648824691772, 0.07660245150327682, 0.047116804867982864, 0.11350055038928986, -0.17153683304786682, -0.11798014491796494, -0.0006862711161375046, 0.05361539497971535, -0.08646862208843231, -0.01791868545114994, 0.0010869887191802263, 0.08865104615688324, -0.04702400788664818, -0.041974812746047974, -0.06557150930166245, 0.06011304259300232, -0.13531631231307983, 0.08650515973567963, 0.0909227728843689, 0.06561270356178284, -0.0966297909617424, 0.010418295860290527, 0.0054579004645347595, -0.05357685685157776, -0.05282728374004364, -0.05420861020684242, -0.061136651784181595, -0.1294911801815033, 0.03053147904574871, 0.05014956742525101, -0.021288301795721054, 0.013483455404639244, -0.13903193175792694, 0.03652516007423401, 0.00016011251136660576, -0.1368444263935089, -0.049332424998283386, -0.08821818977594376, -0.052430953830480576, -0.04692264646291733, -0.042276475578546524, -0.021105315536260605, -0.03012998029589653, -0.019561979919672012, -0.1235566958785057, 0.08157152682542801, -0.06845793128013611, 0.0035264957696199417, 0.11278025060892105, 0.07186981290578842, 0.08396076411008835, -0.0526014007627964, -0.008773397654294968, 0.09936711192131042, -0.016838492825627327, 0.07996760308742523, -0.060629069805145264, -0.11074453592300415, -0.05941613018512726, 0.1728818118572235, -0.017053423449397087, -0.13530080020427704, 0.10371909290552139, 0.08699680864810944, 0.10737630724906921, 0.001653031911700964, 0.17540083825588226, 0.09197293967008591, -0.08993673324584961, 0.021809151396155357, 0.02666018344461918, -0.015467549674212933, -0.20927198231220245, 0.14188873767852783, 0.009086783975362778, -0.050115495920181274, 0.050071872770786285, -0.0013375673443078995, -0.12413772940635681, -0.038489606231451035, 0.2044460028409958, -0.02409449592232704, -0.02741757407784462, 0.04658662527799606, -0.09101729094982147, -1.1947396178023469e-32, -0.05119708180427551, 0.10363710671663284, -0.024591688066720963, -0.14034591615200043, -0.09670674800872803, 0.10052216798067093, 0.10830230265855789, -0.19031277298927307, 0.08143089711666107, -0.12280204892158508, 0.09770111739635468, 0.004431795794516802, -0.08517125248908997, 0.011496186256408691, -0.23058289289474487, 0.16318026185035706, -0.03144153207540512, 0.0031738230027258396, -0.1376919448375702, 0.017643116414546967, 0.08633125573396683, 0.17740647494792938, -0.03742162138223648, 0.02389681152999401, 0.019457831978797913, 0.02350887469947338, 0.07776894420385361, 0.05359122157096863, 0.07007884979248047, -0.06463825702667236, -0.07045574486255646, 0.06874564290046692, -0.19305457174777985, -0.1174190416932106, -0.06061140447854996, 0.04006163775920868, 0.13805925846099854, -0.1924360990524292, -0.04910239204764366, -0.1351318508386612, -0.048302143812179565, 0.019856560975313187, -0.1257360428571701, -0.06523848325014114, 0.12290146201848984, 0.07534712553024292, 0.04613802582025528, -0.018691595643758774, 0.04652942717075348, 0.16035830974578857, -0.04814128205180168, 0.06080596521496773, 0.028729278594255447, 0.024542221799492836, 0.02663276717066765, -0.13544343411922455, 0.03493018448352814, -0.13527056574821472, -0.0577300600707531, 0.01808449625968933, 0.0013762712478637695, 0.10148754715919495, -0.0016421042382717133, -0.009203799068927765, 0.1540229618549347, 0.12525811791419983, 0.12359574437141418, -0.017555637285113335, -0.021023588255047798, -0.015550251118838787, -0.13000616431236267, -0.06307362020015717, -0.027896709740161896, -0.10047245025634766, -0.08680247515439987, 0.1524520218372345, -0.017280464991927147, -0.1388937085866928, -0.16728322207927704, -0.07162952423095703, -0.03580539673566818, -0.05193551629781723, 0.005573388654738665, 0.08677372336387634, 0.04770255833864212, -0.00735175795853138, 0.028225265443325043, 0.028040222823619843, 0.07498811930418015, 0.06370681524276733, -0.12963010370731354, -0.14385604858398438, -0.11127497255802155, 0.11176110804080963, 0.0071375248953700066, -1.0044500697858894e-07, 0.11387688666582108, -0.023274295032024384, 0.06890112906694412, -0.05716490373015404, 0.02975963056087494, 0.07598994672298431, -0.20386233925819397, 0.055327776819467545, -0.053163498640060425, 0.12564831972122192, -0.012305580079555511, 0.09430234879255295, -0.05540234223008156, -0.02700427919626236, -0.07568775117397308, 0.08738776296377182, 0.007025445811450481, -0.02649594470858574, -0.013614369556307793, -0.07966065406799316, -0.06703805178403854, -0.04036213457584381, 0.06514829397201538, -0.08384240418672562, 0.06133224070072174, -0.05109505355358124, 0.0046686576679348946, 0.21260836720466614, 0.031032895669341087, -0.1197575181722641, -0.03628457710146904, -0.04443567246198654, 0.05854097008705139, -0.003305514343082905, 0.012360310181975365, -0.04198087379336357, 0.03858164697885513, 0.10505031049251556, 0.03689015656709671, 0.15140259265899658, 0.023890428245067596, 0.06599709391593933, -0.049699872732162476, 0.06748726963996887, -0.0029677869752049446, -0.06231212615966797, -0.07923254370689392, 0.00606713118031621, 0.12668822705745697, -0.1489855945110321, 0.037770599126815796, -0.045821402221918106, -0.047972679138183594, -0.05147683992981911, 0.016799762845039368, 0.1702241152524948, -0.05624227225780487, -0.01824004389345646, 0.01658218912780285, -0.013993609696626663, 0.10452573746442795, -0.0866113156080246, 0.012271517887711525, -0.03132098168134689], "changes": {"1wk": -15.7187222933944, "1mo": -14.684592193283253}}, {"text": "Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients Cogent Biosciences, Inc. Mon, Dec 9, 2024, 3:00 PM 7 min read In This Article: COGT -3.44% Cogent Biosciences, Inc. 56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS 89% of patients had >50% decrease in serum tryptase by four weeks of treatment and 95% of patients with elevated baseline tryptase achieved serum tryptase levels <20 ng/ml by week 24 SUMMIT Part 2 enrollment completed early; surpassing original enrollment target with 179 patients enrolled, top-line results now expected in July 2025 Cogent to host investor webcast today, Monday, December 9 at 8:00 a.m. ET WALTHAM, Mass. and BOULDER, Colo., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced updated clinical results from the Open Label Extension (OLE) portion of SUMMIT, a clinical trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM). The OLE data are being presented at the 66 th American Society of Hematology (ASH 2024) Annual Meeting & Exposition taking place December 7-10, 2024 in San Diego, CA. \u201cThe rapid, deep, and sustained symptomatic improvement reported by SUMMIT patients receiving bezuclastinib is very impressive,\u201d said Daniel J. DeAngelo, M.D., Ph.D., Chief of the Division of Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine, Harvard Medical School. \u201cCoupled with its favorable tolerability profile, bezuclastinib has clear potential to establish itself as the best-in-class KIT inhibitor for systemic mastocytosis patients.\u201d \u201cThe SUMMIT data reported today are encouraging to thousands of NonAdvSM patients around the world who are waiting for a novel treatment that can rapidly and meaningfully improve a wide variety of symptoms that impact their daily lives,\u201d said Andrew Robbins, Cogent\u2019s President and Chief Executive Officer. \u201cWe set out earlier this year to enroll our registration-directed SUMMIT Part 2 trial, and I\u2019m excited to announce that based on the overwhelming demand from investigators and patients around the world, we\u2019ve completed enrollment in the study with 179 patients more than six months ahead of schedule. Top-line results are now expected in July 2025, meaning we have dramatically accelerated our timeline as we aim to make bezuclastinib available to all NonAdvSM patients.\u201d Patient Demographics SUMMIT is a registration-directed, randomized, double-blind, placebo-controlled, global, multicenter, clinical trial of bezuclastinib in patients with NonAdvSM. In SUMMIT Part 1, patients received bezuclastinib or placebo for a 12-week period to determine the recommended dose for use in the pivotal portion of the trial, SUMMIT Part 2. Earlier this year, Cogent announced that the recommended go-forward dose was selected at once-daily 100 mg. After the initial 12-week period, all patients were given the opportunity to receive bezuclastinib in the SUMMIT Open Label Extension (OLE). The clinical results presented today focus on 27 patients in the OLE who were treated with the once-daily 100 mg dose of bezuclastinib. The median age of patients at study entry was 52 years (ranging from 36-76 years). One patient had received prior avapritinib. Story Continues Patient Reported Outcomes (PRO) Data SUMMIT patients were evaluated for signs of clinical activity over 24 weeks using multiple PRO measures, including the Mastocytosis Symptom Severity Daily Diary (MS2D2) and the Mastocytosis Quality-of-Life (MC-QoL) scale. Updated clinical data presented today show: 56% mean improvement in Total Symptom Score (TSS) at 24 weeks 76% of patients demonstrated >50% reduction from baseline in MS2D2 Total Symptom Score (TSS) with 88% of patients exceeding 30% reduction from baseline after 24 weeks 49% mean improvement in MC-QoL Total Score at 24 weeks At 24 weeks of treatment, 31% of patients have already reduced or discontinued best supportive care (BSC) medications. Pharmacodynamic Data Bezuclastinib showed rapid, deep, and sustained reductions in serum tryptase over the course of 24 weeks of treatment including: 89% of patients had > 50% decrease in serum tryptase levels by four weeks of treatment 95% of patients with baseline tryptase \u226520ng/mL achieved <20ng/mL by week 24 84% of patients with baseline serum tryptase > 11.4ng/ml achieved <11.4ng/mL by week 24 Safety Data As of the data cutoff, August 29, 2024, the median duration of bezuclastinib treatment was 56 weeks for patients in the active arm and 40 weeks for placebo patients who crossed over to the OLE. The majority of treatment emergent adverse events were low grade and reversible with no treatment-related bleeding or cognitive impairment events reported. The most common treatment related adverse events were hair discoloration and transaminase elevations. All patients experiencing elevated transaminases were asymptomatic and reversible: five patients resolved without any dose modifications and remain on study; two patients resolved with dose reduction and remain on study, one of whom re-escalated to original dose; and two patients resolved following discontinuation, one of whom was presented previously at ASH 2023. There were no other discontinuations due to adverse events. SUMMIT Enrollment Update Cogent also announced today that enrollment in the registration-directed SUMMIT Part 2 study is now complete. In the nine months between February and October 2024, 265 NonAdvSM patients were screened for SUMMIT Part 2 at 70 clinical sites, concentrated predominantly in the U.S. and Western Europe. More than 90% of these patients were na\u00efve to KIT inhibitor therapy. A total of 179 patients were enrolled and top-line results from the trial are expected in July 2025. Webcast Information and ASH Poster Cogent will host a webcast today, Monday, December 9, 2024, at 8:00 a.m. ET to discuss these updated SUMMIT clinical results. The live event will be available on the Investors & Media page of Cogent\u2019s website at investors.cogentbio.com . A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.\u00a0The ASH poster is available to registered conference attendees and is also in the Posters and Publications section of Cogent\u2019s website at www.cogentbio.com/research . About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2, PI3K\u03b1 and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn . Information that may be important to investors will be routinely posted on our website and X . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the company\u2019s expectation to present top-line results from SUMMIT Part 2 in July 2025; the potential for bezuclastinib to establish itself as the best-in-class KIT inhibitor for systemic mastocytosis patients; and the company\u2019s goal of making bezuclastinib available to all NonAdvSM patients. The use of words such as, but not limited to, \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"will,\" or \"would\" and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption \"Risk Factors\" in Cogent's most recent Quarterly Report on Form 10-Q filed with the\u00a0SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Contact: Christi Waarich Senior Director, Investor Relations christi.waarich@cogentbio.com 617-830-1653 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "COGT", "date": "2024-12-09T12:00:00+00:00", "sentiment": {"score": 0.9200476529076695, "confidence": 0.932828962802887, "probabilities": {"positive": 0.932828962802887, "negative": 0.012781309895217419, "neutral": 0.05438970401883125}}, "embedding": [0.00037787482142448425, -0.1511460244655609, -0.06109052523970604, 0.025113524869084358, -0.03995788097381592, -0.07430152595043182, -0.14600282907485962, 0.22562149167060852, -0.006216954439878464, 0.0458749495446682, -0.08598057180643082, -0.05524054169654846, 0.026878738775849342, 0.17131257057189941, -0.14311259984970093, 0.030017279088497162, 0.12312280386686325, 0.013490501791238785, -0.033647846430540085, -0.026322992518544197, 0.07232564687728882, 0.030690401792526245, 0.11650557070970535, 0.10066845268011093, -0.06513641029596329, -0.16120553016662598, -0.21377761662006378, -0.05593866854906082, -0.1255524903535843, 0.0558781698346138, -0.11055725812911987, 0.04721604287624359, -0.026776764541864395, -0.007179577369242907, -0.016678716987371445, 0.021641509607434273, -0.06123672053217888, -0.012892578728497028, -0.010551981627941132, -0.08797375857830048, 0.05573008209466934, 0.06423724442720413, -0.01525315921753645, -0.0120594073086977, -0.018049156293272972, -0.10110583901405334, -0.062054313719272614, 0.03983422741293907, -0.012392528355121613, 0.174652561545372, -0.12473207712173462, -0.12436579167842865, 0.0022813081741333008, -0.05310412496328354, -0.01729186624288559, 0.06973341852426529, -0.0625942125916481, -0.03950841352343559, 0.1126236841082573, 0.06634455919265747, -0.004189196042716503, -0.051712021231651306, -0.0588415265083313, 0.004605993162840605, 0.28172099590301514, 0.06354065984487534, -0.04976387694478035, 0.06337019056081772, -0.05131017789244652, 0.004173663444817066, 0.1088031679391861, -0.16023877263069153, 0.050095945596694946, 0.18540512025356293, 0.03541284054517746, 0.07993900030851364, 0.08856354653835297, 0.18783676624298096, 0.0333564430475235, -0.04558214172720909, -0.059572480618953705, 0.014247054234147072, 0.020642491057515144, 0.045813508331775665, 0.03725254908204079, 0.08024340867996216, -0.054577309638261795, 0.2359638214111328, -0.011537844315171242, -0.020727520808577538, 0.1926635056734085, -0.015963435173034668, -0.020577948540449142, 0.03914175182580948, 0.029838062822818756, -0.021528087556362152, -0.052510082721710205, 0.06644098460674286, -0.031176453456282616, -0.0853903517127037, -0.05749867856502533, -0.0614224337041378, -0.1435084044933319, -0.12002570927143097, 0.06440815329551697, -0.040654513984918594, 0.20177271962165833, 0.0019249878823757172, 0.07868276536464691, 0.006261651404201984, -0.07923524081707001, 0.04422501474618912, 0.02659502625465393, -0.02626408264040947, -0.01461262907832861, 0.1845945417881012, 0.038373567163944244, 0.03985920920968056, 0.14531385898590088, 0.04614429548382759, 0.1823933869600296, -0.033654093742370605, 0.07785499095916748, -0.15298032760620117, 0.16796177625656128, 0.1600474715232849, -0.07144378870725632, 9.626453846669881e-33, 0.017802666872739792, 0.07203145325183868, 0.19041387736797333, 0.06443481147289276, -0.05356240272521973, 0.013805772177875042, 0.06662259995937347, -0.07352596521377563, -0.10007422417402267, -0.04708375036716461, -0.1287010908126831, 0.05719136446714401, 0.041639067232608795, 0.12908238172531128, -0.13177278637886047, -0.14015084505081177, -0.010426587425172329, -0.039675649255514145, -0.11193840205669403, -0.004975065588951111, -0.047454677522182465, 0.10844668745994568, 0.0368194505572319, -0.010429700836539268, -0.10547852516174316, 0.07114958018064499, -0.14830155670642853, 0.08501153439283371, 0.06736419349908829, 0.04056761413812637, -0.10419810563325882, 0.07363782823085785, -0.018135419115424156, -0.09260475635528564, -0.03665489703416824, -0.06410904228687286, -0.009795171208679676, -0.09752802550792694, 0.006317272782325745, 0.0022949865087866783, -0.008672747761011124, 0.03348205238580704, -0.15139883756637573, -0.007360100746154785, 0.013658696785569191, -0.1234155148267746, -0.05157691240310669, -0.05721455439925194, 0.00947096198797226, -0.047172144055366516, 0.005089239217340946, -0.05591246113181114, 0.007045156322419643, -0.08895402401685715, -0.09086772799491882, 0.0637250766158104, -0.056305259466171265, 0.03718184307217598, 0.097002312541008, 0.04443620890378952, 0.09037890285253525, -0.05510920286178589, -0.004465028643608093, 0.1188318133354187, -0.026108993217349052, 0.09524071216583252, -0.056268446147441864, -0.10465233027935028, -0.05716286599636078, 0.10973988473415375, -0.00026762718334794044, -0.08779501914978027, 0.12415735423564911, 0.08850162476301193, 0.11451652646064758, 0.012535924091935158, 0.14575113356113434, 0.039366863667964935, -0.08983591198921204, -0.03894719108939171, 0.09469112753868103, -0.020130444318056107, -0.1885014921426773, 0.10567733645439148, 0.03703860938549042, -0.05806698650121689, 0.010959498584270477, 0.017159204930067062, -0.06022444739937782, -0.03447996824979782, 0.12946102023124695, -0.018819665536284447, -0.052613966166973114, 0.09694765508174896, -0.11821558326482773, -9.877424829306317e-33, -0.014054182916879654, 0.13950645923614502, -0.007309422362595797, -0.13750335574150085, -0.05589412525296211, 0.07576560974121094, 0.10949376225471497, -0.17576706409454346, 0.016878265887498856, -0.18617193400859833, 0.11042629927396774, -0.05965171754360199, -0.05860042944550514, 0.006879826541990042, -0.2336873710155487, 0.21049481630325317, -0.05774586647748947, -0.00380090344697237, -0.063938669860363, -0.05732876434922218, 0.0596354603767395, 0.2060859054327011, -0.06254610419273376, -0.009813403710722923, 0.0323915109038353, 0.05042922496795654, -0.007175189908593893, 0.18050560355186462, 0.07621168345212936, -0.11475390940904617, 0.004468503408133984, 0.06855698674917221, -0.1869087517261505, -0.09747245907783508, 0.009412067010998726, 0.060668252408504486, 0.09631235897541046, -0.1529969871044159, 0.01643511839210987, -0.13510861992835999, -0.05700045824050903, 0.009367173537611961, -0.05280422791838646, -0.08837538957595825, 0.13323776423931122, 0.0974418967962265, 0.0165840033441782, -0.08251016587018967, -0.005042321048676968, 0.1202780082821846, -0.056218221783638, 0.00233704736456275, 0.008434741757810116, 0.08976389467716217, 0.06620603054761887, -0.08414869010448456, 0.004817270673811436, -0.11057233810424805, -0.11863984167575836, 0.013277534395456314, -0.0015194860752671957, 0.06836016476154327, -0.0016636569052934647, -0.050593629479408264, 0.1564001739025116, 0.08532832562923431, 0.12428366392850876, 8.53436067700386e-05, 0.039438214153051376, 0.031405508518218994, -0.14806421101093292, -0.19907470047473907, -0.04689027741551399, -0.11185652017593384, -0.12654152512550354, 0.09389641135931015, -0.02813556045293808, -0.08391008526086807, -0.17784897983074188, -0.10535632073879242, -0.07130448520183563, -0.05007953196763992, 0.0022900374606251717, 0.07723399996757507, 0.09886409342288971, -0.022992873564362526, 0.06979905068874359, 0.016288744285702705, 0.14207585155963898, 0.09697342664003372, -0.11653458327054977, -0.12235266715288162, -0.07901392877101898, 0.09306413680315018, 0.044847272336483, -1.0038304765203065e-07, 0.15183424949645996, -0.09454488754272461, 0.019668251276016235, -0.04769936949014664, 0.039370931684970856, 0.06612951308488846, -0.23879526555538177, 0.034607596695423126, -0.04466386139392853, 0.11293038725852966, -0.01239253394305706, -0.023793376982212067, -0.08041219413280487, -0.061203472316265106, -0.0817859023809433, 0.015212859027087688, 0.031951483339071274, 0.023086532950401306, 0.0007889685221016407, -0.07042478024959564, -0.12370181083679199, -0.010780028998851776, 0.08076176047325134, -0.17142489552497864, -0.0203589778393507, -0.049788784235715866, 0.018454764038324356, 0.20303814113140106, -0.036451954394578934, -0.17129351198673248, -0.09203651547431946, -0.001710275188088417, 0.10080123692750931, 0.016733672469854355, -0.011560129001736641, 0.018255313858389854, -0.015518741682171822, 0.12033664435148239, 0.06160135567188263, 0.16224947571754456, 0.07773301005363464, 0.07344846427440643, -0.04295937716960907, 0.08580505847930908, 0.026360096409916878, -0.12320239096879959, -0.0801706537604332, 0.008288765326142311, 0.23063431680202484, -0.1331481635570526, 0.009597623720765114, 0.014172876253724098, -0.052533626556396484, -0.034777309745550156, -0.006926060654222965, 0.1425376832485199, -0.06801547110080719, 0.03939639776945114, 0.001712936908006668, -0.03591277077794075, 0.12345025688409805, -0.12214754521846771, -0.019463244825601578, -0.06309548020362854], "changes": {"1wk": -15.7187222933944, "1mo": -14.684592193283253}}]